1
|
Fabian CJ, Klemp JR, Burns JM, Vidoni ED, Nydegger JL, Kreutzjans AL, Phillips TL, Baker HA, Hendry B, John C, Amin AL, Khan QJ, Mitchell MP, O'Dea AP, Sharma P, Wagner JL, Hursting SD, Kimler BF. Abstract P6-12-11: Feasibility and biomarker modulation due to high levels of moderate to vigorous physical activity as part of a weight loss intervention in older, sedentary, obese breast cancer survivors. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-12-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We sought to demonstrate that older, sedentary, obese breast cancer survivors could achieve > 200 minutes per week of moderate to vigorous physical activity (MVI PA) as part of a weight loss intervention; and to assess modulation of risk biomarkers. This level of PA in combination with moderate calorie restriction is associated with weight losses of >10% in women without cancer, which in turn is associated with significant modulation of cancer risk biomarkers.
Eleven participants with BMI > 30 kg/m2 enrolled in a 12-week program that consisted of moderate caloric restriction, weekly phone group behavioral sessions, and individualized exercise plans based on measured heart rate reserve. Women were provided an accelerometer with heart rate monitor linked to GarminConnect, membership to a YMCA, twice weekly supervised exercise sessions with a personal trainer, and weekly feedback regarding weight and physical activity progress. The goal was to increase MVI PA (≥45% heart rate reserve) gradually from <60 to >200 minutes per week.
The median age was 61, 5/11 women had received prior chemotherapy, and 7/11 were currently taking aromatase inhibitors. Median values of baseline anthropomorphic measures acquired by dual energy x-ray absorptiometry (GE Lunar iDXA) included BMI, 37.3 kg/m2; total mass, 97.5 kg; fat mass, 47.6 kg; visceral fat, 1.7 kg (range 1.4-3.0); and fat mass index, 17.6 kg/m2. The majority had a baseline VO2 peak in the poor range for their age. All 11 participants completed the intervention, with no reported serious adverse events. Median MVI PA achieved over weeks 5-12 was 161 minutes/week (range 48-320). VO2 peak was increased in 10/11 with a median relative change of 12% from baseline. All but one lost weight with an overall median of 8% total mass loss, which was associated with 13% total fat mass loss and 21% visceral fat mass loss. For those with MVI PA above the median, values were 11%, 17%, and 40%, respectively. Visceral fat mass loss was linearly correlated with minutes per week of MVI PA (p=0.032); these parameters in turn were associated with changes in a number of serum biomarkers, including adiponectin-leptin ratio, TNF-alpha, as well as circulating adipose stromal cells, a potential marker for metastasis. Insulin and hs-CRP were favorably modulated in almost all participants but change was not linearly correlated with activity or mass loss parameters; thus these may not be ideal biomarkers to document a dose response to level of MVI PA.
Conclusion: These results demonstrate that older, sedentary, obese breast cancer survivors can safely achieve a high level of MVI PA when provided a structured program that includes an exercise trainer. It is feasible to design a clinical trial for such breast cancer survivors to examine biomarker modulation as a function of level of physical activity.
Citation Format: Fabian CJ, Klemp JR, Burns JM, Vidoni ED, Nydegger JL, Kreutzjans AL, Phillips TL, Baker HA, Hendry B, John C, Amin AL, Khan QJ, Mitchell MP, O'Dea AP, Sharma P, Wagner JL, Hursting SD, Kimler BF. Feasibility and biomarker modulation due to high levels of moderate to vigorous physical activity as part of a weight loss intervention in older, sedentary, obese breast cancer survivors [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-11.
Collapse
Affiliation(s)
- CJ Fabian
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - JR Klemp
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - JM Burns
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - ED Vidoni
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - JL Nydegger
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - AL Kreutzjans
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - TL Phillips
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - HA Baker
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - B Hendry
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - C John
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - AL Amin
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - QJ Khan
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - MP Mitchell
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - AP O'Dea
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - P Sharma
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - JL Wagner
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - SD Hursting
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| | - BF Kimler
- University of Kansas Medical Center, Kansas City, KS; University of North Carolina, Chapel Hill, NC
| |
Collapse
|
2
|
Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Abstract P1-15-01: Final analysis of SWOG S0230/Prevention of early menopause study (POEMS). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: The SWOG S0230/POEMS study demonstrated a 70% reduction in ovarian failure (OF) with goserelin coadministration during chemotherapy (CT) for ER-negative early breast cancer (BC; Moore H et al, NEJM 2015). Goserelin use was also associated with more pregnancies as well as favorable disease free survival (DFS) and overall survival (OS). Here we report the final analysis after 5 years of follow-up.
METHODS: Premenopausal women age <50 with stage I-IIIA ER/PR-negative BC to be treated with cyclophosphamide-containing CT were randomized to receive standard CT with or without monthly goserelin 3.6 mg SQ starting at least 1 week prior to the first CT dose. The primary endpoint was OF at 2-years, defined as amenorrhea for the prior 6 months and post-menopausal FSH. Secondary endpoints included pregnancies, disease free survival (DFS) and overall survival (OS). An unplanned analysis of rate of menses recovery at 2 years (presence of menses within 6 months of the 2 year time-point or pregnancy within the first 2 years) was also conducted. OF and pregnancy endpoints were analyzed using multivariable logistic regression adjusting for stratification factors (age and CT regimen); DFS and OS were examined using multivariable Cox regression, adjusting for stratification factors and stage. Two-sided p-values are reported unless otherwise specified in accordance with protocol design.
RESULTS: Among 257 randomized participants, 218 were eligible and evaluable. One hundred thirty-six eligible and evaluable patients had OF data and 186 had menstrual data. Median age was 37.7 years. Among the 136 patients with OF data, the odds ratio (OR) for OF at 2 years was 0.30 (95% CI 0.1-0.98; one-sided p=0.023) comparing CT with goserelin to standard CT alone. Among 186 patients with menstrual data, 80% recovered menses by 2 years in the goserelin arm compared with 70% in the standard arm (OR=1.74, 95% CI: 0.83-3.66, p=0.15). Pregnancies, DFS and OS are reported for all 218 eligible and evaluable patients. With a median follow-up of 5.1 years, 22% of patients in the goserelin group had at least one pregnancy compared with 12% in the standard group (OR 2.38, 95% CI 1.08-5.26, p=0.03). Cumulative incidence of pregnancy at 5 years is 23% in the goserelin arm compared with 12% in the standard group. Five-year Kaplan-Meier DFS estimates are 88% in the goserelin arm compared with 79% in the standard arm (HR=0.50, p=0.05). Five-year OS is 92% with goserelin versus 83% in the standard arm (HR=0.47, p=0.06). Including all 257 randomized patients, HR for DFS and OS are 0.67 and 0.48 (p=0.18 and p=0.05).
CONCLUSION: Ovarian suppression with goserelin during chemotherapy for hormone receptor-negative breast cancer reduces OF risk and, after 5 years of follow-up, continues to be associated with more pregnancies and improved survival compared with chemotherapy without goserelin.
SUPPORT: NIH/NCI grant awards CA189974, CA180888, CA180819, CA074362; AstraZeneca
Citation Format: Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Moseley A, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final analysis of SWOG S0230/Prevention of early menopause study (POEMS) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-15-01.
Collapse
Affiliation(s)
- HCF Moore
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - JM Unger
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - K-A Phillips
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - F Boyle
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - E Hitre
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - A Moseley
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - D Porter
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - PA Francis
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - LJ Goldstein
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - HL Gomez
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - CS Vallejos
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - AH Partridge
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - SR Dakhil
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - AA Garcia
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - J Gralow
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - JM Lombard
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - JF Forbes
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - S Martino
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - WE Barlow
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - CJ Fabian
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - L Minasian
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - FL Meyskens
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - RD Gelber
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - GN Hortobagyi
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| | - KS Albain
- Cleveland Clinic, Cleveland, OH; SWOG Statiscial Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Peter MacCallum Cancer Center, Melbourne, VIC, Australia; University of Sydney, Sidney, NSW, Australia; National Institute of Oncology, Budapest, Hungary; Aukland Regional Cancer Center and Blood Service, Auckland, New Zealand; Fox Chace Cancer Center, Philadelphia, PA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Oncosalud SAC, Lima, Peru; Dana Farber Cancer Institute, Boston, MA; Cancer Center of Kansas, Wichita, KS; Louisiana State University Health Sciences Center, New Orleans, LA; Seattle Cancer Care Alliance, Seattle, WA; Calvary Mater Newcastle, Waratah, NSW, Australia; Australia and New Zealand Breast Cancer Trials Group, Callaghan, NSW, Australia; The Angeles Clinic and Research Institute, Santa Monica, CA; University of Kansas, Westwood, KS; National Cancer Institute, Bethesda, MD; University of California at Irvine, Orange, CA; University of Texas MD Anderson Cancer Center, Houston,
| |
Collapse
|
3
|
Fabian CJ, Kimler BF, Umar S, Ahmed I, Befort CA, Nydegger JL, Kreutzjans AL, Powers KR, Klemp JR, Spaeth KR, Sullivan DK. Abstract P4-13-03: Changes in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-13-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Change in the relative composition of the gut microbiome at the phyla level, particularly decreases in Bacteroidetes and increases in Firmicutes species, has been associated with both obesity and increased risk for breast cancer. It is unclear how rapidly the microbiome changes in response to a reduced calorie and fat diet during a weight loss intervention. As a planned sub-study of a clinical trial with a structured behavioral weight loss intervention with randomization to high dose omega-3 fatty acids or placebo (NCT02101970; clinical trials.gov), we evaluated changes in the gut microbiome after 2 weeks of dietary intervention.
Methods
46 post-menopausal women at increased risk for breast cancer with a BMI > 27 kg/m2 had a baseline 3 day food record, DXA, and blood and breast tissue sampling for biomarkers. They were then started on a reduced fat and calorie diet (~1200 kcal/day from 2 portion-controlled entrees, 3 low calorie high protein shakes, and 5 servings of fruits/vegetables daily), recommendation to exercise 225 minutes per week, and a weekly behavioral intervention. Fecal samples were collected at baseline, after 2 weeks of diet but prior to study agent, and after 6 months of weight loss intervention. Stool samples were stored at -20°C until brought to the clinic, and then at -80°C until DNA extraction. Bacterial taxonomic classification was performed using real-time PCR and 16S pyrosequencing using specific 16S rRNA primers. Baseline Healthy Eating Index (HEI) was calculated from the 3 day food record; fruit and vegetable servings were obtained from weekly food logs.
Results
42 women completed the 6 month weight loss intervention. At baseline, median BMI was 31.0 kg/m2 and HEI was 58 (range 28-90) with 12 and 23 servings of fruits and vegetables per week. Median relative weight loss at 6 months was -11.9 % (0 to -22.7 %). When dichotomized to relative losses of <10% vs >10% (which we have previously shown to be associated with significant improvement in blood and breast tissue risk biomarkers [Fabian Cancer Prev Res 2013]), women with 6 month >10% loss had favorable change in the two major stool phyla at 2 weeks with a median 10% increase for Bacteroidetes and 8% decrease for Firmicutes. Conversely, women with <10% loss showed a decrease (median -11%) in Bacteroidetes and an increase (median 16%) for Firmicutes. Fruit and vegetable consumption also differed between the weight loss groups. The >10% loss group had higher baseline consumption of vegetables and continued this after starting the diet. The more adherent a woman was to dietary recommendations in the first weeks of dietary intervention, the more likely she was to lose >10% weight by 6 months.
Conclusions
Favorable modulation of the gut microbiome early in a weight loss intervention is associated with subsequent substantial weight loss. Microbiome assessment after 6 months of weight loss intervention is in progress.
Supported by a grant from the Breast Cancer Research Foundation and pilot funds from National Cancer Institute Cancer Center Support Grant P30 CA168524.
Citation Format: Fabian CJ, Kimler BF, Umar S, Ahmed I, Befort CA, Nydegger JL, Kreutzjans AL, Powers KR, Klemp JR, Spaeth KR, Sullivan DK. Changes in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-13-03.
Collapse
Affiliation(s)
- CJ Fabian
- University of Kansas Medical Center, Kansas City, KS
| | - BF Kimler
- University of Kansas Medical Center, Kansas City, KS
| | - S Umar
- University of Kansas Medical Center, Kansas City, KS
| | - I Ahmed
- University of Kansas Medical Center, Kansas City, KS
| | - CA Befort
- University of Kansas Medical Center, Kansas City, KS
| | - JL Nydegger
- University of Kansas Medical Center, Kansas City, KS
| | - AL Kreutzjans
- University of Kansas Medical Center, Kansas City, KS
| | - KR Powers
- University of Kansas Medical Center, Kansas City, KS
| | - JR Klemp
- University of Kansas Medical Center, Kansas City, KS
| | - KR Spaeth
- University of Kansas Medical Center, Kansas City, KS
| | - DK Sullivan
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
4
|
Befort CA, Klemp JR, Sullivan DK, Diaz FJ, Schmitz KH, Perri MG, Fabian CJ. Abstract P3-08-02: Comparison of strategies for weight loss maintenance among rural breast cancer survivors: The rural women connecting for better health randomized controlled trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-08-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer survivors who reside in rural areas represent one of the largest medically underserved populations of breast cancer survivors in the nation and have higher obesity prevalence compared to their urban counterparts. Given the evidence linking obesity with poor breast cancer prognosis, trials are needed to demonstrate ability to produce long-term weight loss maintenance in this hard-to-reach group. Group phone-based counseling via conference calls is a low-technology approach with excellent reach to rural areas. This treatment delivery approach capitalizes on the support benefits of in-person groups by allowing participants to interact in real time while also diminishing costs.
Methods: In this 2 phase trial, overweight and obese (BMI 27 to 45 kg/m2) rural breast cancer survivors (with initial stage 0-III disease) were randomized to one of two extended care interventions for weight loss maintenance (Phase 2) subsequent to an initial 6-month weekly group phone-based behavioral weight loss intervention (Phase 1). To be eligible for randomization for maintenance, participants must have lost ≥ 5% of their baseline weight during Phase 1. In Phase 2, participants were randomized to continued group phone-based counseling reduced in frequency to every other week during maintenance vs every other week mailed newsletters that followed the same content.
Results: 210 breast cancer survivors with a mean time since treatment of 3.5 years ± 2.4 years, mean age of 58.1 ± 9.9 years, and mean BMI of 33.9 ± 4.4 kg/m2 residing in a three state region of the rural Midwest were entered in the 6-month weight loss phase. Retention from baseline to 6 months (Phase 1) was 91%. Mean percent weight loss at 6 months for the total sample was 12.9% with 82% of enrolled participants ≥ 5% below baseline weight. 172 participants with a mean initial loss of 14.0% of baseline weight (12.8 ± 4.9 kg) were randomized to a maintenance intervention. Retention from 6 to 18 months (Phase 2) was 92%. Intent-to-treat analyses with imputation of missing data revealed participants in the group phone condition regained less weight (3.3 ± 4.8 kg) compared to participants in the newsletter condition (4.9 ± 4.8 kg; p = 0.03). Mean percent weight loss from baseline to 18 months did not significantly differ between the group phone condition (10.2 ± 7.5%) and the newsletter condition (9.2 ± 7.9%). However, at 18 months 75.3% of participants in the group phone condition remained ≥ 5% below baseline weight compared to 57.8% in the newsletter condition (p = .02).
Discussion: The initial group phone-based weight loss intervention exceeded typical weight losses reported in the literature with over 80% of enrolled participants achieving clinically meaningful weight loss. Continued group phone counseling was modestly better in sustaining weight loss at 18 months than a mailed newsletter. However, for both maintenance approaches, the majority of participants maintained a weight at 18 months that was 5% or more below baseline.
Citation Format: Befort CA, Klemp JR, Sullivan DK, Diaz FJ, Schmitz KH, Perri MG, Fabian CJ. Comparison of strategies for weight loss maintenance among rural breast cancer survivors: The rural women connecting for better health randomized controlled trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-08-02.
Collapse
Affiliation(s)
- CA Befort
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - JR Klemp
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - DK Sullivan
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - FJ Diaz
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - KH Schmitz
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - MG Perri
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - CJ Fabian
- University of Kansas Medical Center; University of Pennsylvania; University of Florida
| |
Collapse
|
5
|
Khan QJ, Barr JA, Britt AS, Kimler BF, Connor CS, McGinness M, Mammen JMV, Wagner JL, Amin A, Springer M, Baccaray S, Fabian CJ, Sing AP, Sharma P. Abstract P5-13-03: Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-13-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aromatase inhibitors (AIs) are effective in reducing the risk of recurrence from breast cancer (BC) but 20% of patients (pts) with early BC still recur despite adjuvant AIs. Thus more effective endocrine therapies (HTs) are needed. In metastatic BC (MBC), combination of lower dose fulvestrant plus anastrozole improves survival compared to anastrozole alone. The 21-gene Recurrence Score® (RS; Oncotype DX®) has been validated to predict benefit from adding chemotherapy (CT) to HT where pts with a low score have little benefit from CT and derive a large benefit from HT. Ki-67 response to neo-adjuvant HT may predict adjuvant outcomes to HT. Postoperative Endocrine Prognostic Index (PEPI) and modified PEPI may further identify a subset of HT sensitive cancers that do not require adjuvant CT (PEPI 0 category). We conducted a single arm phase II trial to assess the efficacy of fulvestrant plus anastrozole as neoadjuvant HT in pts with operable BC.
Methods: Postmenopausal pts with stage II and III, ER/PR+, HER2 (-) BC with a RS<25 (performed on initial core bx) were included. Duration of neo-adjuvant HT was 4 months. Pts received anastrozole 1mg (PO) daily continuously from day 1 until surgery + fulvestrant (IM) 500mg on day 1, 14 and 28 of cycle 1, and on the last day of three subsequent 28 day cycles (total 6 doses of fulvestrant). At week 4, an optional core bx was repeated to assess change in Ki-67. Response assessments were made clinically every 4 wks. All pts had breast/axillary surgery after the 6th dose of fulvestrant. Ki-67, histologic grade, ER/PR status, and RS were assessed at baseline, core bx at 4 wks, and at definitive surgery. Primary end points were pathologic complete response (pCR) rate and change in Ki-67. Adjuvant CT was left to the discretion of treating physician.
Results: 42 pts were enrolled 7/2009 to 11/2014. Median age was 62. 32 (76%) patients had stage IIA, 7 (17%) had stage IIB and 3 (7%) had stage III disease. 14% had clinically node positive disease. The median RS was 12 (0-24). Median tumor size was 3.5cm. 21%, 74%, and 5% had grade 1, 2 and 3 tumors respectively. Mean ER expression was 95%. 16 (38%) pts had a clinical complete response (cCR), 13 (31%) had a clinical partial response (cPR) and 12 (29%) had stable disease. One pt had progression on therapy. There were no pCRs. Median baseline Ki-67 was 5% (1-36%). 94% of pts had decrease in Ki-67 from baseline to 4-week bx and 97% of pts had decrease in Ki-67 from baseline to surgery. Modified PEPI score at surgery was 0 in 53% of patients. 78% of pts did not receive adjuvant CT. At median follow up of 38 mos only 1 pt had a recurrence with 98% free of a recurrence. There were no grade 3 or grade 4 toxicities.
Conclusions: The neoadjuvant combination of anastrozole and fulvestrant in pts with RS<25 markedly improves Ki-67 response with more than half of pts achieving a modified PEPI score of 0 at surgery. At a relatively short median follow up, recurrence rate is very low. Given the efficacy and tolerability of anastrozole plus fulvestrant in MBC and now in the neo-adjuvant setting, an adjuvant trial of this combination is warranted in pts with ER+ BC.
Citation Format: Khan QJ, Barr JA, Britt AS, Kimler BF, Connor CS, McGinness M, Mammen JMV, Wagner JL, Amin A, Springer M, Baccaray S, Fabian CJ, Sing AP, Sharma P. Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-13-03.
Collapse
Affiliation(s)
- QJ Khan
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - JA Barr
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - AS Britt
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - BF Kimler
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - CS Connor
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - M McGinness
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - JMV Mammen
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - JL Wagner
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - A Amin
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - M Springer
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - S Baccaray
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - CJ Fabian
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - AP Sing
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| | - P Sharma
- The University of Kansas Medical Center, Kansas City, KS; Genomic Health, Redwood City, CA
| |
Collapse
|
6
|
Bowers LW, Ford NA, Rossi EL, Shamsunder MG, Kimler BF, Fabian CJ, Hursting SD. Abstract P2-05-28: The impact of the plant lignin secoisolariciresinol diglycoside on preclinical models of estrogen receptor positive breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-05-28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Several preclinical studies indicate that secoisolariciresinol diglycoside (SDG), a polyphenolic plant lignin found most abundantly in flaxseeds, inhibits the progression of both estrogen receptor (ER) positive and negative mammary tumors. SDG is metabolized by gut bacteria into the biologically active metabolites enterolactone (ENL) and enterodiol (END), which are known to have anti-estrogenic activity. However, the mechanisms mediating SDG's anti-tumor effects remain poorly understood.
Methods: In a dose-determination pilot study linked to an ongoing clinical trial of SDG in women at high risk for breast cancer, 18 week old C57BL/6 mice were randomized to a control diet or SDG-supplemented diets (25 or 74 mg/kg of food) for 8 weeks prior to euthanization, and the levels of serum and tissue SDG metabolites (particularly ENL and END), metabolic hormones and inflammatory markers were measured. In an ongoing tumor study, 12-week old C57BL/6 and foxn1 nu/nu mice were randomized to the control or control plus SDG (100 mg/kg of food, a dose projected to match ENL and END metabolite levels achieved in the clinical trial) diet regimen. After 8 weeks on diet, they will receive orthotopic injections of E0771 mouse mammary tumor cells or BT-483 human breast cancer cells (both ER positive), continuing on the same diets until euthanization. Cell culture studies examining the impact of biologically relevant concentrations of ENL and END on E0771 and BT-483 cells are also in progress.
Results: In comparison to those maintained on the control diet, the higher dose SDG diet reduced estrogen and pro-inflammatory signaling in the pilot study mice, as evidenced by higher interleukin 10 and lower C-reactive protein mammary fat pad expression as well as lower circulating levels of the adipokines leptin and resistin, which have been linked to chronic inflammation. High dose SDG also decreased serum insulin and glucose levels, indicating improved metabolic function. Because serum ENL and END levels in the pilot study did not reach those achieved in the SDG clinical trial, a 100 mg/kg SDG dose was chosen for the tumor study. Cell culture studies indicate that ENL (150 nM) inhibits E0771 and BT-483 cell proliferation and ER alpha:beta expression ratio.
Conclusions: Preliminary data suggests that the anti-tumor effects of SDG's metabolites may be mediated through multiple mechanisms, including improvements in metabolic function and inflammatory signaling as well as modulation of breast cancer cell gene expression. The results of the ongoing tumor study will inform the design of additional cell culture studies aimed at further defining these mechanisms.
Citation Format: Bowers LW, Ford NA, Rossi EL, Shamsunder MG, Kimler BF, Fabian CJ, Hursting SD. The impact of the plant lignin secoisolariciresinol diglycoside on preclinical models of estrogen receptor positive breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-28.
Collapse
Affiliation(s)
- LW Bowers
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| | - NA Ford
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| | - EL Rossi
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| | - MG Shamsunder
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| | - BF Kimler
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| | - CJ Fabian
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| | - SD Hursting
- University of North Carolina at Chapel Hill; University of Texas at Austin; University of Kansas Medical Center
| |
Collapse
|
7
|
Barr JA, Sharma P, Fabian CJ, Yeh H, Baccaray S, Springer M, Khan QJ. Abstract OT3-01-12: Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-01-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Although the treatment of HER2 positive metastatic breast cancer (MBC) has improved with anti-HER2 agents and chemotherapy, most patients will eventually develop resistance to these agents. Preclinical studies have shown that mTOR inhibition may reverse trastuzumab resistance. We hypothesize that combining mTOR inhibitor everolimus with lapatinib will be an effective strategy for patients who have progressed on prior anti-HER2 therapies.
Trial Design:
We are conducting an open-label phase II pilot study of the combination of everolimus and lapatinib for pts with HER-2 positive MBC. Eligible pts must have histologically documented locally advanced (inoperable) or metastatic HER-2 positive breast cancer that have progressed on at least one HER-2 based regimen in the metastatic or locally advanced setting. Pts with disease progression during or within 12 mos of the completion of adjuvant trastuzumab are eligible. Pts with untreated asymptomatic brain metastases are allowed. Pts with symptomatic brain metastases are allowed to enroll after they have completed radiation and are off steroids. Eligible pts are started on everolimus 5 mg PO daily and lapatinib 1250 mg PO daily without interruption. Among subjects progressing on lapatinib, lapatinib is continued and everolimus initiated. Pts will continue to receive treatment until there is evidence of progressive disease (PD), unacceptable toxicity, or withdrawal of consent. Pts will have radiological evaluation every 8 weeks with CT, bone scan, and MRI brain (for pts with known brain metastasis at baseline).
Specific Aims:
Primary objective is to assess the effectiveness of the combination of RAD-001 and lapatinib as measured by the six-month Overall Response Rate in women with MBC who have progressed on trastuzumab and/or lapatinib based therapies. Secondary objectives are six-month PFS, safety and tolerability of the combination, six-month objective CNS response rate, six-month clinical benefit rate of systemic disease, and six-month clinical benefit rate in CNS.
Statistical methods:
The response rate of lapatinib monotherapy in heavily pre-treated patients is estimated to be 7% (Blackwell 2009). For an expected ORR of 17%, a sample size of 45 subjects will provide 79% power to detect the difference at 0.10 Type I error rate according to 1-sided exact binomial test.
Present accrual and target accrual:
The trial has accrued 20 patients with a target accrual of 45 patients.
Citation Format: Barr JA, Sharma P, Fabian CJ, Yeh H, Baccaray S, Springer M, Khan QJ. Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-01-12.
Collapse
Affiliation(s)
- JA Barr
- University of Kansas Cancer Center, Westwood, KS
| | - P Sharma
- University of Kansas Cancer Center, Westwood, KS
| | - CJ Fabian
- University of Kansas Cancer Center, Westwood, KS
| | - H Yeh
- University of Kansas Cancer Center, Westwood, KS
| | - S Baccaray
- University of Kansas Cancer Center, Westwood, KS
| | - M Springer
- University of Kansas Cancer Center, Westwood, KS
| | - QJ Khan
- University of Kansas Cancer Center, Westwood, KS
| |
Collapse
|
8
|
Fabian CJ, Kimler BF, Petroff BK, Zalles CM, Metheny T, Nydegger JL, Box JA, Phillips TL, Hidaka BHH, Carlson SE, deGraffenried LA, Hursting SD. Abstract P4-10-01: High dose omega-3 fatty acid supplementation modulates breast tissue biomarkers in post-menopausal women at high risk for development of breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-10-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We conducted a pilot study of high dose omega-3 fatty acid (FA) supplementation in post-menopausal women to determine if risk biomarkers for breast cancer in benign breast tissue sampled by random peri-areolar aspiration (RPFNA) could be favorably modulated and to acquire preliminary data on possible mechanism of action.
Methods: 35 post-menopausal women at increased risk for breast cancer were accrued to a trial of 6-month intervention with 4 g daily of omega-3-acid ethyl esters [1.86 g eicosapentaenoic acid (EPA), 1.5 g docosahexaenoic acid (DHA)]. Subjects had RPFNA performed pre- and post-intervention and specimens evaluated for cytomorphology and proliferation (Ki-67). FA composition was determined in plasma, red blood cells, and RPFNA specimens. Additional specimens were frozen for assessment of hormones, a panel of 11 adipokines and cytokines by Luminex, and gene expression.
Results: 34 subjects completed study with specimens evaluable for change in biomarkers. The ratio of (EPA+DHA):Arachidonic Acid (AA) levels in erythrocyte phospholipid increased significantly by a median of 2.7-fold. Although there was a significant decrease in blood EPA+DHA between discontinuation at 6 months and 2 weeks later when RPFNA was performed, all ratios were above the baseline value (median 1.6-fold). There was favorable but not statistically significant modulation for cytologic evidence of atypia (53% at baseline to 41% at off-study). However, favorable modulation was exhibited for Masood score (medians of 15 to 14; p = 0.014), number of epithelial cells recovered (p = 0.019) and Ki-67 expression (medians of 1.7% to 0.75%, p = 0.036, despite 8 subjects having no Ki-67 expression at baseline). Luminex assay of serum indicated a statistically significant increase (p = 0.003) for adiponectin and decrease (p = 0.016) for TNF-alpha between baseline and off-study. For RPFNA specimens, there was a significant decrease (P = 0.001) in MCP-1 levels adjusted for protein content. By ELISA, serum high molecular weight adiponection increased (p = 0.046) and molar ratio of IGF-1:IGFBP3 decreased (p = 0.006). Note that all analyses were exploratory and without correction for multiple analyses.
Conclusion: Favorable modulation of a variety of blood and tissue risk biomarkers, including cytomorphology and proliferation, along with good tolerability suggests that high dose omega-3 FA esters should be tested further in a placebo-controlled trial.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-10-01.
Collapse
Affiliation(s)
- CJ Fabian
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - BF Kimler
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - BK Petroff
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - CM Zalles
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - T Metheny
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - JL Nydegger
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - JA Box
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - TL Phillips
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - BHH Hidaka
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - SE Carlson
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - LA deGraffenried
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| | - SD Hursting
- University of Kansas Medical Center, Kansas City, KS; Mercy Hospital, Maimi, FL; University of Texas, Austin, TX
| |
Collapse
|
9
|
Burnett D, Klemp JR, Porter C, Schmitz KJ, Fabian CJ, Kluding P. Abstract P2-11-17: Pilot Study to Evaluate a Home-based Exercise and Weight Loss Intervention on Cardiopulmonary Fitness and Markers of Breast Cancer Risk in Postmenopausal Breast Cancer Survivors. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-11-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: BrCa survivors have an estimated 4-fold increase in risk for developing cardiovascular disease compared to women never treated for breast cancer and a nearly 3-fold increase in breast cancer mortality in women with an exercise capacity (VO2max) less than 28mL kg−1 min−1. Cardiac events are the second most common cause of death in long-term breast cancer (BrCa) survivors.
Purpose: We conducted a study to investigate the effects of standard exercise or structured exercise on targeted cardiovascular outcomes during a home-based diet and exercise intervention for breast cancer survivors.
Method: Cross-sectional within- and between-group design. A total of 19 breast cancer survivors, average age of 52.6+/−9.3, were enrolled in the study. A convenient sample was enrolled into two exercise groups receiving either: standard (150 minutes per week of usual care (exercise without instruction) cardiovascular exercise + resistance training) or structured (150 minutes per week of gradual increased intensity cardiovascular exercise + resistance training) exercise instruction along with a group based behavioral weight loss intervention. All participants underwent baseline and 17 week assessments including maximal exercise testing (VO2max and minutes on the treadmill), measurements of body composition (weight, BMI, % body fat), and assessment of quality of life.
Results: We report on the 16 participants who completed the baseline and 17 week assessments (9 = Standard Exercise Group; 7 = Structured Exercise Group). The structured exercise group exhibited significantly greater improvements in measures of cardiorespiratory fitness: VO2max (p = 0.05) and duration on treadmill (p = 0.02). No significant differences were noted for all other cardiorespiratory fitness testing outcomes. Significant improvements from baseline to 17 weeks were seen across both groups for all measures of body composition. Lean body mass did not significantly change from baseline to 17 weeks in both groups. There were no significant between group differences for change in body composition.
Conclusion: In this study, both standard exercise and structured exercise improved CR fitness measured by VO2max, but the structured exercise group experienced significantly greater improvements.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-11-17.
Collapse
Affiliation(s)
- D Burnett
- University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA
| | - JR Klemp
- University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA
| | - C Porter
- University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA
| | - KJ Schmitz
- University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA
| | - CJ Fabian
- University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA
| | - P Kluding
- University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
10
|
Sharma P, Stecklein S, Kimler BF, Klemp JR, Khan QJ, Fabian CJ, Tawfik OW, Connor CS, McGinness MK, Mammen JMW, Jensen RA. Abstract PD09-02: BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum based chemotherapy. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd09-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Triple negative breast cancer (TNBC) and BRCA1-associated breast cancers share many histopathologic and molecular features. BRCA1 plays a crucial role in HR-dependent DNA repair and BRCA1-deficient cells are particularly susceptible to the DNA damaging agents like platinums. Increasing evidence suggests that in addition to germline BRCA defects, other mechanisms (like epigenetic BRCA1 silencing) can lead to BRCA1 insufficiency in TNBC. However, the impact of BRCA1 insufficiency on the efficacy of DNA damaging agents in TNBC is not known.
Aim: To investigate the impact of BRCA1 insufficiency on relapse-free survival (RFS) and overall survival (OS) in patients with stage II-III TNBC treated with neoadjuvant platinum-based chemotherapy. BRCA1 insufficiency (BRCA1insuf) state was defined as presence of germline BRCA1/2 mutation or BRCA1 promoter methylation (PM) and/or low BRCA1 expression (lowest quartile).
Methods: Thirty patients with stage II/III TNBC received neoadjuvant chemotherapy (6 cycles of Carboplatin AUC 6, Docetaxel 75mg/m2 and Erlotinib 150 mg PO) on a phase II trial between 8/2007–6/2010. All but one patient underwent comprehensive BRCA analysis (Myriad Genetic Laboratories). Pre-treatment tumor specimens were used for evaluation of BRCA1 PM and expression. Genomic DNA was isolated from FFPE samples, bisulfite converted and then subjected to methylation-specific PCR (MSP). RNA was isolated, reverse transcribed to cDNA and assayed by quantitative real-time PCR (qRT-PCR) for determination of BRCA1 mRNA transcript levels. RFS and OS were estimated according to the Kaplan-Meier method and compared among groups with log-rank statistic. Cox proportional hazards models were fit to determine the association of BRCA1insuf with the risk of death after adjustment for other characteristics.
Results: Median age: 51yrs, African American: 20%, Median tumor size: 3.3 cm, LN positive: 40%. Six of 30 patients (20%) harbored germline BRCA mutation (4 BRCA1, 2 BRCA2). Baseline tumor specimen was available for 26/30 patients. BRCA1 MSP was successful in 92% and BRCA1 qRT-PCR was successful in 84% of specimens. BRCA1 PM and low BRCA1 expression was present in 30% and 15% of subjects, respectively. There was evidence of BRCA1insuf in 53% (16/30) of subjects. At a median time from diagnosis of 42 months (range, 23–59 months) there have been 9(30%) recurrences and 7(23%) deaths. On univariate analysis node negativity, lower stage and presence of BRCA1insuf were associated with better OS. At the median follow up, RFS is 81% for patients with BRCA1insuf versus 54% for patients without BRCA1insuf (p = 0.16); OS is 83% for patients with BRCA1insuf versus 46% for patients without BRCA1insuf (p = 0.021). After adjustment for clinical variables patients with BRCA1insuf had a significantly better OS compared to patients without BRCA1insuf (p = 0.036).
Conclusions: Germline BRCA testing plus tissue BRCA1 PM/expression can be used to identify a BRCA1insuf sub-population within TNBC demonstrating a favorable outcome with platinum treatment. This BRCA1insuf criteria can be easily used to select TNBC patients likely to benefit from DNA damaging agents like platinums and PARP inhibitors.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD09-02.
Collapse
Affiliation(s)
- P Sharma
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - S Stecklein
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - BF Kimler
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - JR Klemp
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - QJ Khan
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - CJ Fabian
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - OW Tawfik
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - CS Connor
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - MK McGinness
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - JMW Mammen
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| | - RA Jensen
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
11
|
Goss PE, Richardson H, Ingle JN, Chlebowski RT, Fabian CJ, Garber JE, Sarto GE, Hiltz A, Tu D, Cheung AM. P4-11-13: Influence of Two Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer; a Companion Study to the NCIC CTG MAP.3 Trial. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-11-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Exemestane significantly reduced invasive and preinvasive breast cancers in postmenopausal women at increased risk for breast cancer in the NCIC CTG MAP3 trial with no serious toxicities, including excess fractures or osteoporosis.
Purpose: To provide additional information on the effect of exemestane on bone loss in women at high risk for breast cancer, within a subset of women participating on the NCIC CTG MAP.3B study. The primary hypothesis is that exemestane does not induce clinically significant bone loss in postmenopausal women at increased risk of developing breast cancer at 2 years. The primary objective of this companion study is to examine the effect of exemestane on lumbar spine and total hip BMD by DEXA at 2 years in women participating in the MAP3 trial.
Methods: The MAP.3B bone sub-study registered women from the main MAP. 3 trial from May 2008 to March 2010. Eligible women had to have an acceptable quality BMD scan by DEXA taken within 12 months prior to randomization to MAP.3. A BMD T-score >-2.0 SD (i.e. better than 2 standard deviations below the average peak BMD of a young adult woman) was established as the study population cutoff. A questionnaire including information on height, falls, fractures, lifestyle information including physical activity, tobacco and alcohol use was completed at baseline, 12 months, 24 months and at last visit. Fasting serum for bone biomarkers was collected at 12 months and total hip and L1-L4 (postero-anterior) spine BMD were measured 2 years after randomization on the same Lunar or Hologic scanner. The primary objective was to determine differences in hip and spine BMD at 2 years. Secondary outcomes include number of skeletal fractures and development of osteoporosis 2 years after randomization and changes in bone biomarkers at 1 year after randomization. For the analysis of the primary endpoints, the upper limit of a one sided 95% confidence interval for the difference in mean percentage changes between placebo and exemestane will be calculated for the BMD by DEXA at each site. We will conclude that exemestane does not induce significant bone loss in postmenopausal women at increased risk of developing breast cancer at 2 years when the upper limit is less than 3% for both sites. Similar confidence interval approach will be used to analyze the secondary endpoints.
Results: Between May 2008 and March 2010, 238 postmenopausal women were recruited. Median age was 61.8 years, and the majority of women were Caucasian (91%), with approximately 20% of the participants reporting a recent fall (within past 12 months) and another 13% reporting a recent fracture prior to randomization. We will report results from the primary as well as the secondary endpoints at the SABCS meeting.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-11-13.
Collapse
Affiliation(s)
- PE Goss
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - H Richardson
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - JN Ingle
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - RT Chlebowski
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - CJ Fabian
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - JE Garber
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - GE Sarto
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - A Hiltz
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - D Tu
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| | - AM Cheung
- 1Massachusetts General Hospital Cancer Center, Boston, MA; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Dana Farber Cancer Institute, Boston, MA; Center for Women's Health and Health Research, Madison, WI; General Hospital, Toronto, ON, Canada
| |
Collapse
|
12
|
Maunsell E, Richardson H, Ingle JN, Ales-Martinez JE, Chlebowski RT, Fabian CJ, Sarto GE, Garber JE, Pujol P, Hiltz A, Tu D, Goss PE. S6-1: Menopause-Specific and Health-Related Qualities of Life among Post-Menopausal Women Taking Exemestane for Prevention of Breast Cancer: Results from the NCIC CTG MAP.3 Placebo-Controlled Randomized Controlled Trial. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-s6-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Exemestane, a steroidal aromatase inhibitor, reduced the incidence of invasive breast cancers by 65% among 4560 post-menopausal randomized to exemestane or placebo for 5 years on MAP.3. Differences in quality of life (QOL) were judged to be minimal, but only summary information was reported.
Purpose: To provide more detailed information about effects of exemestane on menopause-specific and health-related qualities of life.
Method: Participation in quality of life assessment was an eligibility criterion. Menopause-specific and health-related qualities of life were assessed using the MENQOL (4 scales; physical, vasomotor, psychosocial, sexual) and SF-36 (8 scales; physical health, role function — physical, bodily pain, general health, vitality, social function, role function — emotional, mental health, and 2 summary scales) instruments, respectively at baseline, 6 months and then yearly after randomization. Compliance with QOL questionnaire completion at each follow-up visit ranged from 93–98%, and did not differ by group. Change scores for each MENQOL and SF-36 scale, calculated for each assessment time relative to baseline, were compared using the Wilcoxon Rank-Sum test. Summary scores were used to summarize the QOL scores observed at each time point for each SF-36 dimension and overall mental (MCS) and physical component summaries (PCS) and MENQOL domains. Clinically important worsening of MENQOL change scores was defined as an increase of ≥0.5/8 points. SF-36 change scores were considered worsened if scores decreased by ≥ 5 points from baseline.
Results: Both groups were balanced on scores for MENQOL and SF-36 at baseline. Median follow-up was 35 months and the proportion of women who stopped study medication early for toxicity reasons was 15% in the exemestane arm and 11% in the placebo arm. There was a statistically significant difference in change scores for vasomotor symptoms among women on exemestane during the first 4 years (p-values <0.01), compared to placebo. However, no between-group differences in vasomotor change met the criterion for clinical importance. Women on exemestane had statistically poorer sexual functioning (mean change = −0.02, SD=1.37) compared to placebo (mean change = −0.12, SD=1.32) during the first 6 months on study (p-value = 0.03) but the differences were not statistically significant thereafter or clinically important at any time. Among the 8 SF-36 scales, only bodily pain was statistically different between exemestane and placebo for the first 24 months on study medication (p-value <0.01), but no between-group difference in change scores exceeded 5 points. Overall SF-36 PCS and MCS assessing changes in overall physical and mental health-related QOL did not differ significantly by group at any assessment.
Conclusion: Our assessment that early differences in vasomotor symptoms and pain were probably not clinically important is supported by the observation of no between-group differences when overall physical and mental health-related QOL changes were compared. Exemestane does not appear to have a major negative impact on the quality of life among these women.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr S6-1.
Collapse
Affiliation(s)
- E Maunsell
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - H Richardson
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - JN Ingle
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - JE Ales-Martinez
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - RT Chlebowski
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - CJ Fabian
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - GE Sarto
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - JE Garber
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - P Pujol
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - A Hiltz
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - D Tu
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| | - PE Goss
- 1Université Laval, Quebec City, QC, Canada; Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Hospital Ntra Sra Sonsoles, Avila, Spain; Los Angeles Biomedical Research Institute, Torrance, CA; University of Kansas Medical Center, Westwood, KS; Center for Women's Health and Health Research, Madison, WI; Dana Farber Cancer Institute, Boston, MA; CHU-Hopital Arnaud de Villeneuve, Montpellier, France; Massachusetts General Hospital Cancer Center, Boston, MA
| |
Collapse
|
13
|
Harvey KE, Li S, Carlson SE, Sullivan DK, Klemp JR, Kimler BF, Fabian CJ. P3-09-03: Long-Chain Polyunsaturated Fatty Acid Intake and Its Relationship to Long-Chain Polyunsaturated Fatty Acids in Serum, Red Blood Cells and Breast Tissue. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Long chain omega-3 (n-3) poly unsaturated fatty acids (LCPUFA) have anti-inflammatory effects and are able to counteract the effects of the pro-inflammatory omega-6 (n-6) fatty acids such as arachidonic acid (AA) by substituting for the n-6 fatty acids in triglycerides (TG) and phospholipids (PL). Several pre-clinical, observational, and case control studies suggest that intake or tissue content of n-3 LCPUFA such as eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), relative to intake or tissue content of long chain n-6 fatty acids such as AA may be associated with reduced risk of breast cancer. The goal of this study was to determine the relationships between dietary intake of fatty acids, tissue levels of fatty acids, and breast tissue biomarkers for risk of breast cancer.
Methods: Women (n=74) were recruited from a clinic in which women at increased risk for breast cancer had breast tissue acquired by random periareolar fine needle aspiration (RPFNA). Breast epithelial cells were assessed for cytomorphology and proliferation (Ki-67 immunochemistry). Fatty acid dietary intake was assessed with the National Cancer Institute Diet History Questionnaire. Plasma, erythrocyte, and breast specimens were processed for membrane PL and TG and analyzed for individual fatty acids by gas liquid chromatography.
Results: Total intake of n-3 PUFA was 1.1 ± 0.5 g/d, and the ratio of EPA+DHA:AA was 0.1:1.0 (n=66). Dietary n-3 LCPUFA correlated with n-3 LCPUFA in both plasma and erthyrocyte PL (n=62). Breast epithelial cell number, Masood cytomorphology score, and percent Ki-67 positive cells were higher in RPFNA specimens which exhibited cytologic atypia compared to those which did not (n=74; p<0.001, Mann-Whitney Test). Subjects with atypia consumed less dietary n-3 PUFA (n=66, p=0.020), had lower plasma and erythrocyte PL and plasma TG EPA, DHA, total n-3, and EPA+DHA:AA (n=70; p<0.05). In breast tissue TG, the ratio of n-3:n-6 was also lower in subjects with atypia (n=40; p=0.025).
Conclusions: Overall, women in this high risk cohort consumed very low amounts of n-3 LCPUFAs. Dietary intake of n-3 LCPUFA was related to levels of n-3 LCPUFA in erythrocyte and plasma PL. Given the association of low levels of n-3 fatty acids with cytologic atypia (a known risk factor for breast cancer development), an intervention to increase n-3 fatty acids and n-3:n-6 ratios has merit and clinical trials in high risk women have been initiated.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-09-03.
Collapse
Affiliation(s)
- KE Harvey
- 1University of Kansas Medical Center, Kansas City, KS
| | - S Li
- 1University of Kansas Medical Center, Kansas City, KS
| | - SE Carlson
- 1University of Kansas Medical Center, Kansas City, KS
| | - DK Sullivan
- 1University of Kansas Medical Center, Kansas City, KS
| | - JR Klemp
- 1University of Kansas Medical Center, Kansas City, KS
| | - BF Kimler
- 1University of Kansas Medical Center, Kansas City, KS
| | - CJ Fabian
- 1University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
14
|
Befort CA, Klemp JR, Austin HL, Krigel S, Sullivan DK, Schmitz KH, Perri MG, Fabian CJ. P4-12-07: Outcomes of a Behavioral Weight Control Intervention among Rural Breast Cancer Survivors. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-12-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Obese breast cancer survivors have 1.5 to 2.5 fold increased risk of recurrence and death compared to their normal weight counterparts. Rural women, who comprise over 20% of the U.S. population of women, have significantly higher obesity rates as well as breast cancer treatment-related disparities. Thus, weight control intervention is a key strategy for secondary breast cancer prevention in this population. However, access can be challenging in the rural setting. Using conference call technology to deliver group-based intervention is well-suited for rural breast cancer survivors because it is easily accessible and provides real-time peer support. The purpose of this one-arm treatment study was to examine the impact of a 6-month group phone-based behavioral weight control intervention on anthropomorphic, diet, physical activity, and psychosocial/quality of life outcomes.
Methods: Eligible participants were post-menopausal breast cancer survivors (Stage I-IIIc, 3 months to 10 years since surgery, radiation, or chemotherapy, < 75 years of age, BMI 27–45 kg/m2) who resided in a rural area. The weight control intervention included a reduced calorie diet with 2 prepackaged meals and ≥5 fruit and vegetables servings daily, home-based physical activity gradually increased to 225 min/week of moderate intensity exercise, weekly self-monitoring logs, and weekly 60-minute group phone sessions that addressed behavioral modification and breast cancer survivorship topics. Group size ranged from 9 to 13 women. Measures included anthropometrics, two 24-hour dietary recall interviews, and questionnaires measuring physical activity, fatigue, depression, body image and sexuality, and self-efficacy for diet and physical activity behavior change. Results: Participants (n = 34) were 58.9 ± 7.8 years-old, 3.1 ± 1.6 years out from treatment, had a baseline BMI of 33.7 ± 4.4 kg/m2, and 63% were on anti-hormone therapy. Average sessions attendance among all participants, including 3 non-completers, was 90%. Ninety-one percent of participants (n = 31) attended > 75% of intervention sessions and completed post-treatment data collection visits. At 6 months, significant changes were observed for weight (−12.5 ± 5.8 kg, 13.9% of baseline weight), waist circumference (−9.4 ± 6.3 cm), daily energy intake (−349 ± 550 kcal/day), fruits and vegetables (+3.7 ± 4.3 servings/day), percent kcal from fat (−12.6 ± 8.6%), and physical activity (+1235 ± 832 kcal/week; all p's < .001). Significant improvements were also seen for Body Image subscales (Strength and Health, Social Barriers, Appearance and Sexuality), Depression, and Self-Efficacy for diet and physical activity behaviors (all p's < .05). Discussion: The intervention produced significant improvements in weight, diet, physical activity, and quality of life outcomes that compare favorably to the literature. The group phone-based treatment delivery approach appears feasible and effective for weight control intervention among obese rural breast cancer survivors.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-12-07.
Collapse
Affiliation(s)
- CA Befort
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - JR Klemp
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - HL Austin
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - S Krigel
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - DK Sullivan
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - KH Schmitz
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - MG Perri
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| | - CJ Fabian
- 1University of Kansas Medical Center; University of Pennsylvania; University of Florida
| |
Collapse
|
15
|
Goss PE, Ingle JN, Ales-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba504] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA504 Background: Limited efficacy and serious toxicities have limited uptake of tamoxifen or raloxifene as preventatives of breast cancer. Aromatase inhibitors (AIs) prevent contralateral breast cancers more than tamoxifen in adjuvant trials and have fewer serious side effects. This is the first report of an AI used in primary prevention. Methods: NCIC CTG MAP.3 is a randomized trial designed to detect a 65% reduction in annual incidence of invasive breast cancer (IBC) on exemestane (E) versus placebo (P). Eligible postmenopausal women had ≥ one of the following risk factors: Gail score >1.66%, prior ADH, ALH, LCIS or DCIS with mastectomy, age over 60. Health-related and menopause-specific quality of life (QOL) were assessed by SF-36 and MENQOL questionnaires. Results: From 2004-2010, 4,560 women were randomized: age 62.5 yrs (37-90); Gail Score 2.3 % (0.6-21); BMI 28.0 kg/m2 (15.9-65.4). Risk factors included: age >60 yrs (49%); Gail score >1.66 (40%); and prior ADH, ALH, LCIS or DCIS with mastectomy (11%). At median follow-up of 35 months there were 11 IBCs on E and 32 on P (annual incidence 0.19% vs 0.55%; HR= 0.35, 95% CI 0.18-0.70, p = 0.002); ductal (10E/27P), lobular (1E/5P). Most tumors were ER positive (7E/27P); Her2/neu negative (10E/26P); TNM stage T1 (8E/28P), N0 (7E/22P), M0 (11E/30P). E was superior in all subgroups: by Gail score, age, BMI, prior LCIS and DCIS. The annual incidence rate of IBC or DCIS was 0.35% E and 0.77% P (HR=0.47;95% CI 0.27-0.79; p = 0.004) based on 64 IBCs or DCISs (20E/44P). Clinical bone fractures, osteoporosis, hypercholesterolemia or cardiovascular events were equal in both arms. No clinically meaningful differences in QOL were detected. Conclusions: Exemestane significantly reduced invasive and pre-invasive breast cancers in postmenopausal women at increased risk for breast cancer with no serious toxicities. Exemestane should be considered a new option for primary prevention of breast cancer. Supported by the Canadian Cancer Society; Pfizer Inc. PEG supported in part by Avon Foundation.
Collapse
Affiliation(s)
- P. E. Goss
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. N. Ingle
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. Ales-Martinez
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - A. Cheung
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - R. T. Chlebowski
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. Wactawski-Wende
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - A. McTiernan
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. Robbins
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - K. Johnson
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - L. Martin
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - E. Winquist
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - G. Sarto
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - J. E. Garber
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - C. J. Fabian
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - P. Pujol
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - E. Maunsell
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - P. Farmer
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - K. A. Gelmon
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - D. Tu
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| | - H. Richardson
- Massachusetts General Hospital, Boston, MA; Mayo Clinic, Rochester, MN; Hosp Ruber Internacional, Madrid, Spain; Universtiy Health Network, Toronto, ON, Canada; Harbor-UCLA Medical Center, Torrance, CA; University of Buffalo, Buffalo, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; University of California, Davis, Sacramento, CA; University of Tennessee Health Science Center, Memphis, TN; George Washington University School of Medicine, Washington, DC; London Health Sciences Centre, London, ON,
| |
Collapse
|
16
|
Goss PE, Ingle JN, Ales-Martinez J, Cheung A, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson K, Martin L, Winquist E, Sarto G, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized, placebo-controlled clinical trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Cigler T, Richardson H, Yaffe MJ, Fabian CJ, Johnston D, Ingle JN, Nassif E, Brunner RL, Wood ME, Pater JL, Hu H, Qi S, Tu D, Goss PE. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat 2011; 126:453-61. [PMID: 21221773 DOI: 10.1007/s10549-010-1322-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2010] [Accepted: 12/19/2010] [Indexed: 01/14/2023]
Abstract
We hypothesized that exemestane (EXE) would reduce mammographic breast density and have unique effects on biomarkers of bone and lipid metabolism. Healthy postmenopausal women were randomized to EXE (25 mg daily) or placebo (PLAC) for 12 months and followed for a total of 24 months. The primary endpoint was change in percent breast density (PD) between the baseline and 12-month mammograms and secondary endpoints were changes in serum lipid levels, bone biomarkers, and bone mineral density (BMD). Ninety-eight women were randomized (49 to EXE; 49 to PLAC) and 65 had PD data at baseline and 12 months. Among women treated with EXE, PD was not significantly changed from baseline at 6, 12, or 24 months and was not different from PLAC. EXE was associated with significant percentage increase from baseline in N-telopeptide at 12 months compared with PLAC. No differences in percent change from baseline in BMD (lumbar spine and femoral neck) were observed between EXE and PLAC at either 12 or 24 months. Patients on EXE had a significantly larger percent decrease in total cholesterol than in the PLAC arm at 6 months and in HDL cholesterol at 3, 6, and 12 months. No significant differences in percent change in LDL or triglycerides were noted at any time point between the two treatment arms. EXE administered for 1 year to healthy postmenopausal women did not result in significant changes in mammographic density. A reversible increase in the bone resorption marker N-telopeptide without significant change in bone specific alkaline phosphatase or BMD during the 12 months treatment period and 1 year later was noted. Changes in lipid parameters on this trial were modest and reversible.
Collapse
Affiliation(s)
- T Cigler
- Weill Cornell Medical College, New York, NY, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Fabian CJ, Kimler BF, Phillips TA, Zalles CM, Klemp JR, Malone LM, Hursting SD. Abstract PD09-04: Weight Loss in Postmenopausal Women Is Associated with Modulation of Serum and Tissue Based Risk Biomarkers. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd09-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In a pilot study, a structured program of reduced energy diet, physical activity, and weekly group behavioral intervention with other high risk women was successful at producing a median 11% weight loss with at least a 5% weight loss in 88% of subjects. We evaluated the association of weight loss with changes in serum and breast tissue risk and mechanisms of action biomarkers. Methods
High risk postmenopausal women with BMI >25 kg/m2 had breast tissue harvested by random periareolar fine needle aspiration (RPFNA) before and after a 6-month energy balance intervention. Specimens were evaluated for biomarkers including cytomorphology, proliferation (immunocytochemical Ki-67), gene expression by RT-qPCR, and expression of cytokines and adpokines by Luminex assay. Fasting serum was assayed for insulin, glucose, adiponectin, leptin, high sensitivity CRP, IL-6, prolactin, SHBG, estradiol and testosterone using ELISA or Luminex.
Results
For 24 biomarker evaluable subjects, 21 had >5% weight loss (median = 11%). Cytologic atypia was present in 10/24 at baseline and 4/24 at 6 months (p=0.034). For 20 subjects with sufficient cells for assessment of Ki-67 at both times, median baseline Ki-67 was 0.7% and off study 0.3%, with a median change of -0.2% (p=0.19). Statistically significant changes (≥0.003; Wilcoxon) were observed for serum levels of adiponectin, adiponectin:leptin ratio, and SHBG (increases); and leptin, bioavailable estradiol and hsCRP (decreases). Reduction was also observed for insulin (p=0.018) and bioavailable testosterone (p=0.033). These results were duplicated (p≥0.014) by Luminex for adiponectin, leptin, adiponectin: leptin ratio, and insulin; plus hepatocyte growth factor (HGF, decrease). Also, an increase in the adiponectin:leptin ratio was observed for the RPFNA specimens (p=0.012). Gene expression (RT-qPCR) of pS2 was significantly modified (decrease, p=0.035). Further, the weight loss (expressed as relative change) was highly statistically correlated with change (relative) in serum leptin, adiponectin:leptin ratio, SHGB, and free estradiol; as well as with relative change in adiponectin:leptin ratio in RPFNA specimens. Conclusion
Weight loss in high risk postmenopausal women is accompanied by significant modulation of numerous serum and breast tissue-based biomarkers. For several risk and response biomarkers there is a significant correlation between change in the biomarker and the weight loss achieved. This suggests the possibility of identifying mechanisms of action and signaling pathways for dietary/energy balance interventions that may reduce risk for development of breast cancer.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD09-04.
Collapse
Affiliation(s)
- CJ Fabian
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| | - BF Kimler
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| | - TA Phillips
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| | - CM Zalles
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| | - JR Klemp
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| | - LM Malone
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| | - SD. Hursting
- University of Kansas Medical Center, Kansas City; Cedar Park Regional Medical Center, Cedar Park, TX; University of Texas, Austin
| |
Collapse
|
19
|
Fabian CJ, Klemp JR, Kimler BF, Aversman S, Phillips TA, Zalles CM, Sullivan D, Smith B, Donnelly J, Yeh H. Effect of successful weight loss program on biomarkers for breast cancer in postmenopausal high-risk women. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1522] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
O'Dea AP, Thirunavu M, Nydegger J, Klemp JR, Kimler BF, Fabian CJ. Low bone density in premenopausal women at high risk for breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1532 Background: Tamoxifen when used in the high estrogen milieu of premenopausal women may reduce bone density. However, the proportion of premenopausal women at increased risk for breast cancer who have low bone density and are likely to take tamoxifen is unknown. Methods: Premenopausal women attending a high-risk clinic were invited to take part in an ongoing prospective study assessing bone mineral density (BMD) loss. Women on bisphosphonates or those previously treated with selective estrogen receptor modulators were excluded. BMD was measured by DEXA, serum 25-hydroxyvitamin D (25OHD) by chemiluminescence, and information on risk factors for osteoporosis and breast cancer was obtained by questionnaire. Results: 106 premenopausal women were entered between April and October 2008. Median age was 42 (range 23–57), median body mass index (BMI) was 25 kg/m2 (range 15–44). All but two were Caucasian. 13% had a prior biopsy with atypical hyperplasia (AH) or in situ carcinoma, 36% had a family history of osteoporosis, 56% took calcium supplements, and 47% took vitamin D supplements. Median sun exposure was 480 minutes per month, the majority with sunscreen. Median serum 25OHD was 34 ng/ml. Five had deficiency (< 20 ng/mL), and 45 women deficiency or insufficiency (< 32 ng/mL). Seven subjects ages 31 to 48 had evidence of low BMD (T-score of less than -1.0 in the spine or hip.) One woman with low BMD by DEXA had a 25OHD level < 32 ng/ml. Women with low BMD had lower BMIs (median of 22 vs. 25 kg/m2, p = 0.020) than women with normal bone density. There was no difference in history of vitamin D and calcium supplement use, and low 25OHD levels did not explain the low T-scores. Information on vitamin D receptor polymorphisms associated with BMD loss is pending. Importantly, 21% of women with a prior biopsy demonstrating AH or in situ carcinoma had evidence of bone density loss compared to 4% of women without such a biopsy (p = 0.048). Conclusions: Premenopausal women with a history of AH or in situ carcinoma are most likely to take tamoxifen for primary prevention and in our ongoing study have a high enough incidence of low bone density to make baseline assessment by DEXA a consideration, particularly for those with predisposing factors such as low BMI and lack of sun exposure. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. P. O'Dea
- University of Kansas, Westwood, KS; Appleton Medical Center, Appleton, WI
| | - M. Thirunavu
- University of Kansas, Westwood, KS; Appleton Medical Center, Appleton, WI
| | - J. Nydegger
- University of Kansas, Westwood, KS; Appleton Medical Center, Appleton, WI
| | - J. R. Klemp
- University of Kansas, Westwood, KS; Appleton Medical Center, Appleton, WI
| | - B. F. Kimler
- University of Kansas, Westwood, KS; Appleton Medical Center, Appleton, WI
| | - C. J. Fabian
- University of Kansas, Westwood, KS; Appleton Medical Center, Appleton, WI
| |
Collapse
|
21
|
Fabian CJ, Khan QJ, Sharma P, Baxa S, Metheny T, Zalles CM, Kimler BF. Evaluation of Ki-67 measured in benign breast tissue acquired from premenopausal women treated with a flaxseed derivative. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1507 Background: The lignans enterolactone and enterodiol are derived from the action of gut bacteria on ingested secoisolariciresinol diglycoside (SDG) which is commonly found in flaxseed. Enterolactone and enterodiol are thought to impair mammary carcinogenesis via reduction in aromatase activity and the mid-cycle surge of luteinizing hormone. We assessed the modulatory activity of 1 year of SDG on a number of risk biomarkers for breast cancer in a prospective phase II pilot study. We report the effect of SDG on the primary endpoint, proliferation in benign breast tissue as measured by Ki-67 immunocytochemistry, in the first 35 women completing study. Methods: Premenopausal women age 21 to 55 at increased risk for breast cancer underwent a baseline random periareolar fine needle aspiration (RPFNA) between the first and tenth days of their menstrual cycle. Those with RPFNA evidence of hyperplasia and Ki-67 greater than or equal to 2% were invited to participate. Women taking flaxseed or oral contraceptives were ineligible. All women took one Brevail (lignan research) capsule containing 50 mg of SDG daily. Ki-67 staining was performed with DAKO M7240 antibody on hematoxylin counterstained slides and the number of cells staining positive in 500 cells within hyperplastic clusters was counted. Results: Forty-nine women were enrolled on study between February 2006 and June 2008. Of these, four stopped prematurely, 10 women have not completed, and 35 have completed study and undergone follow-up RPFNA. Baseline characteristics of the 35 women completing study are as follows: median age 44 (range 29–50), median baseline 5-year Gail model risk 1.6% (range 0.1%-5.7%), median Ki-67 4.2% (range 2.0%-16.8%). Thirty seven percent had hyperplasia without atypia, and 63% had atypia. At repeat RPFNA, Ki-67 expression was reduced (median value of 2.0%, range 0%-15.2%); with 29 of the 35 women demonstrating a decrease (median relative reduction of 0.70). Conclusions: Based upon reduction in Ki-67 expression in hyperplastic benign breast tissue after 12 months, 50 mg of SDG administered daily as Brevail appears promising as a preventive. Supported in part by grant R21 CA117847 from the National Cancer Institute. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| | - Q. J. Khan
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| | - P. Sharma
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| | - S. Baxa
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| | - T. Metheny
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| | - C. M. Zalles
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS; Cedar Park Regional Medical Center, Cedar Park, TX
| |
Collapse
|
22
|
Khan QJ, Kimler BF, Sharma P, Reddy PS, Baxa S, Klemp JR, Fabian CJ. Vitamin D levels during and after high-dose vitamin D supplementation in women with early-stage breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20561 Background: Experts define vitamin D deficiency as a 25-hydroxyvitamin D (25OHD) level of < 20 ng/ml; a level < 32 ng/ml is considered insufficient for bone health and > 40 ng/ml may be associated with optimum musculoskeletal function and reduced risk for breast cancer. We conducted a study to determine the effect of high dose vitamin D3 at 50,000 IU/wk (HD vitD) on musculoskeletal symptoms from adjuvant letrozole in breast cancer patients. We present here the effectiveness of HD vitD in achieving optimum 25OHD levels and the rate of decline of 25OHD levels after 12 weeks of HD vitD. Methods: The cohort included post-menopausal women with early stage hormone receptor positive breast cancer initiating letrozole treatment. Women with baseline 25OHD levels < 40 ng/ml received 12 weeks of HD vitD. 25OHD levels were assessed at 6 and 12 weeks during HD vitD supplementation and at 3 and 6 months after completing HD vitD but while taking maintenance dose of 600–1000 IU of vitamin D3 daily. Results: 40 women that received HD vitD completed the follow-up phase of the study and are included in this analysis. At entry on study, median 25OHD level was 23 ng/ml; 38% of the women had vitD deficiency, 75% had insufficiency, and 93% had 25OHD levels < 40 ng/ml. Six weeks of HD vitD increased median 25OHD level to 60 ng/ml and another 6 weeks increased it further to 66 ng/ml. With only 6 weeks of HD vitD supplementation, 98% of the women achieved a 25OHD level of > 40 ng/ml. Median 25OHD levels 3 and 6 months after completion of HD vitD were 49 and 40 ng/ml, respectively. The median rate of decrease in vitD levels per month was 6.8% of the level at completion of supplementation. Using linear regression analysis, projected changes in 25OHD levels were calculated for each subject. Median extrapolated time to drop to a 25OHD level of < 40 ng/ml was 6.0 months, to <32 ng/ml was 7.8 months, and to <20 ng /ml was 10.6 months. Conclusions: Supplementation with vitD3 at 50,000 IU/week for 6 weeks is sufficient to achieve a 25OHD level of >40 ng/ml in 98% of postmenopausal women with breast cancer on an AI. After 12 weeks of HD vitD, there is a steady decline in 25OHD levels at a rate of about 7% per month despite continuing on 600 to 1000 IU of D3 daily. Thus, standard doses of D3 are not adequate to maintain 25OHD levels achieved by HD vitD. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Q. J. Khan
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| | - B. F. Kimler
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| | - P. Sharma
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| | - P. S. Reddy
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| | - S. Baxa
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| | - J. R. Klemp
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| | - C. J. Fabian
- University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS; Cancer Center of Kansas, Wichita, KS
| |
Collapse
|
23
|
Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa S, O’dea AP, Fabian CJ. Effect of high-dose vitamin D on joint pain and fatigue from adjuvant letrozole. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Abstract
The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women. Approximately 185,000 new cases of invasive breast cancer are diagnosed yearly, and at least half of these women are both postmenopausal and eligible for adjuvant therapy with AIs. In addition, AIs are currently being tested as primary prevention therapy in large randomised trials involving tens of thousands of women at increased risk for breast cancer. Given the volume of use, internists will increasingly see postmenopausal women who are taking or considering treatment with AIs. Physicians need to be able to: (i) briefly discuss the pros and cons of using a selective estrogen receptor modulator such as tamoxifen or raloxifene vs. an AI for risk reduction and (ii) recognise and manage AI-associated adverse events. The primary purpose of this review is to help internists with these two tasks.
Collapse
Affiliation(s)
- C J Fabian
- Breast Cancer Prevention Center, Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160-7418, USA.
| |
Collapse
|
25
|
Blum JL, Pruitt B, Fabian CJ, Rivera RR, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Fields SZ, Vahdat L. Phase II study of eribulin mesylate (E7389) halichondrin b analog in patients with refractory breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1034 Background: Eribulin is a structurally simplified analog of halichondrin B, which inhibits microtubule dynamics via a novel mechanism characterized by suppression of microtubule growth, lack of effect on microtubule depolymerization, and sequestration of tubulin into nonfunctional aggregates. This study was designed to assess the activity and tolerance of eribulin in chemotherapy refractory patients with advanced breast cancer. Methods: Eribulin was evaluated in a single-arm Phase II trial in female patients with refractory breast cancer, ECOG performance status of 0–1, measurable disease, and neuropathy ≤ Grade 2. Patients received ≥ 1 prior chemotherapy regimen, including an anthracycline and a taxane. Eribulin was administered as a 2–5 min IV bolus of 1.4 mg/m2 on Days 1, 8, and 15 of a 28-Day cycle (Group 1). The schedule was modified to Days 1 and 8 of a 21-Day cycle (Group 2), because of dose delays. The primary efficacy endpoint was ORR according to RECIST criteria based upon independent review (IR) of tumor assessment. Results: Of 104 patients enrolled, 103 received eribulin treatment: 70 in Group 1, 33 in Group 2. Median age was 55 yrs (range 32–84). Patients had received a median of 4 prior chemotherapy regimens (range 1–11). Sixty-one percent of tumors were ER+, 14% Her2/neu 3+, and 29% were triple (ER, PR, Her-2) negative. The incidence of dose interruption, delay, or omission during Cycle 1 was 63% (Group 1) and 18% (Group 2). The most common drug related toxicities were neutropenia (75%, Grades 3: 31%, Grade 4: 30%, febrile neutropenia: 3.9%), fatigue (52%, Grade 3: 2.9%, no Grade 4), alopecia (Grade 1/2: 41%), nausea (37%, Grade 3: 1%, no Grade 4), and anemia (36%, Grade 3: 1%, no Grade 4). Peripheral neuropathy occurred in 34% of patients (Grade 3: 3.9%, no Grade 4). Best overall response rate (all PR) by IR was 14.5% and 15.2% in Groups 1 and 2, respectively; the combined ORR was 14.7% (95 % CI: 9–23%). Median PFS was 85 days, and the 6 mo PFS rate was 31%. Conclusions: Eribulin given as a 2–5 min IV infusion on Days 1, 8 of a 21-Day cycle or Days 1, 8, 15 of a 28-Day cycle exhibited a 15% PR rate by IR and a low incidence of Grade 3 neuropathy in this heavily chemotherapy pretreated population. The most common toxicity was neutropenia. The 21-Day schedule had an acceptable toxicity profile. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. L. Blum
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - B. Pruitt
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - C. J. Fabian
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - R. R. Rivera
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - D. E. Shuster
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - N. L. Meneses
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - K. Chandrawansa
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - F. Fang
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - S. Z. Fields
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| | - L. Vahdat
- Baylor Charles A. Sammons Cancer Center, Dallas, TX; Harrington Cancer Center, Amarillo, TX; University of Kansas Medical Center, Kansas City, KS; Texas Oncology PA and US Oncology, El Paso, TX; Eisai Medical Research, Ridgefield Park, NJ; Weill Cornell Medical College, New York, NY
| |
Collapse
|
26
|
Sharma P, Klemp JR, Kimler BF, Khan QJ, Smith EJ, Fabian CJ. BRCA1 and BRCA2 germline mutation carriers have a lower breast density compared to high risk women without such mutations. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1517 Background: High mammographic breast density, a known risk factor for breast cancer is influenced by both genetic and non genetic factors. It is not clear if there are differences in breast densities between BRCA1/2 mutation carriers and high-risk non carriers. The aim of this study was to compare breast density in high-risk women with and without BRCA1/2 mutation. Methods: Women at high risk for development of breast cancer (based on family history, prior precancerous disease or prior breast cancer) who underwent genetic testing at the University of Kansas Breast Cancer Prevention Center between 1998 and 2005 were identified under an IRB approved protocol. BRCA1/2 full sequencing was performed at Myriad Genetic Laboratories. The earliest digitized mammogram of these subjects was identified from a preexisting mammogram database. All mammograms had to be prior to/at least one year from any chemoprevention intervention. For subjects with prior breast cancer, mammogram of the uninvolved breast was used. Breast density was assessed on the left craniocaudal mammographic view by computer assisted method, Cumulus. Frequencies of categorical variables were assessed using chi-square analysis. Continuous variables were assessed using Mann-Whitney non parametric test. Multiple regression analysis was used to investigate whether differences are due to variables other than mutation status. Results: The study population consisted of 284 high-risk women who underwent BRCA1/2 testing and for whom a mammogram was available. 30 (11%) had BRCA1 and/or 2 deleterious mutation. There was no difference between mutation carriers and non-carriers for BMI, 5 year Gail risk, parity, menopausal status and HRT use. Mutation carriers were younger (median age 42 vs. 46, p=0.020) and more likely to have a positive family history (100% vs. 85%, p=0.020). Older age (p<0.001), higher BMI (p<0.001) and having a BRCA1/2 mutation (p=0.025) were significantly associated with a lower breast density. Conclusion: Among high risk women, possession of a deleterious BRCA1/2 mutation is associated with lower breast density after adjusting for factors known to affect breast density. This suggests that breast density may be governed by genetic factors other than BRCA1/2 mutation status. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Sharma
- University of Kansas Medical Center, Kansas City, KS
| | - J. R. Klemp
- University of Kansas Medical Center, Kansas City, KS
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS
| | - Q. J. Khan
- University of Kansas Medical Center, Kansas City, KS
| | - E. J. Smith
- University of Kansas Medical Center, Kansas City, KS
| | - C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
27
|
Abstract
558 Background: Integrated FDG-PET/CT improves the diagnostic accuracy of staging of some cancers. The value of FDG-PET/CT in initial staging of breast cancer for detection of distant metastases has not been defined. Methods: Retrospective analysis of 83 consecutive women at the University of Kansas Medical Center who had a FDG-PET/CT from Jan 2005 to July 2006, at the time of initial diagnosis of invasive breast cancer. Women with symptoms suspicious for metastatic disease were excluded. Radiographic reports and patient charts were reviewed. All suspicious CT scans were re-read by a single radiologist who was blinded to the PET results. All suspicious scans were confirmed either by a biopsy or follow-up scans according to the discretion of the treating physician. Results: Median age was 52. 23 (28%) cancers were stage I, 44 (53%) stage II and 16 (19%) were stage III. 15/83 (18%) women had a suspicious FDG-PET/CT. Only 2 of these 15 women were confirmed to have metastatic disease, while 13 (16 %) had a false positive (FP) scan. In 5 women where both CT and PET were suspicious, 2 were true positives (TP) whereas 3 were FP. All 3 women who had suspicious PET but a non-suspicious CT were FP. All 7 women who had a non-suspicious PET and a suspicious CT were FP. PET influenced the CT classification by the radiologist in 5 (6%) women. 71/83 (86%) women had a negative or a non-suspicious CT. 3 women had lesions classified as non-suspicious with the help of a negative PET, two had lesions classified as suspicious with the help of a positive PET and seven had suspicious lesions on CT regardless of the PET. FDG-PET/CT resulted in unnecessary follow-up scans in eleven women, and unnecessary biopsies in two. One TP had metastatic bone disease. The other TP had a solitary liver metastasis detected by FDG-PET/CT which was resected and she has no evidence of disease after two years of follow-up. Conclusions: Given the high false positive rate and overall low incidence of metastases, routine use of FDG- PET/CT in asymptomatic women diagnosed with invasive breast cancer cannot be recommended. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Q. J. Khan
- Univ of Kansas Medcl Ctr, Kansas City, KS
| | | | - R. Dusing
- Univ of Kansas Medcl Ctr, Kansas City, KS
| | - P. Sharma
- Univ of Kansas Medcl Ctr, Kansas City, KS
| | | | | | | |
Collapse
|
28
|
Khan QJ, Kimler BF, Smith EJ, O’Dea AP, Sharma P, Fabian CJ. Correlation of mammographic breast density with Ki-67 expression in benign breast epithelial cells obtained by random periareolar fine needle aspiration of high risk women. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1011
>Background: Known risk factors for breast cancer development include elements incorporated into the Gail risk model, mammographic breast density and cytologic atypia detected by Random Periareolar Fine Needle Aspiration (RPFNA). Ki-67 expression is a possible risk biomarker and is currently being used as a response biomarker in chemoprevention trials. We have previously shown that Ki-67 expression is higher in RPFNA specimens of benign breast cells exhibiting cytologic atypia. It is not known whether there is a correlation between mammographic density and Ki-67 expression in benign breast ductal cells obtained by RPFNA. Methods: 344 women at high risk of developing breast cancer (based on personal or family history) seen at The University of Kansas Medical Center high risk breast clinic, who underwent RPFNA with cytomorphology and Ki-67 assessment, plus a mammogram were included in the study. Mammographic breast density was assessed using the Cumulus program. Categorical variables were analyzed by Chi-square test and continuous variables were analyzed by non-parametric test and linear regression. Results: 40% of women were premenopausal, 7% perimenopausal and 53% were postmenopausal. Median age was 49 years, median 5 year Gail Risk was 2.2%, and median Ki-67 was 1.9%. Median mammographic breast density was 37%. Ki-67 expression increased with cytologic abnormality and number of cells collected, but was unrelated to Gail risk (as observed previously). Breast density was higher in pre-menopausal women (p=0.001), those with lower BMI (p< 0.001), and lower 5-year Gail risk (p=0.012); Breast density showed no correlation with Ki-67 expression or cytomorphology. Conclusion: Given the lack of correlation of mammographic breast density with either cytomorphology or Ki-67 expression in RPFNA specimens, mammographic density and Ki-67 expression should be considered as potentially complementary response biomarkers for breast cancer chemoprevention trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Q. J. Khan
- University of Kansas Medical Center, Kansas City, KS
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS
| | - E. J. Smith
- University of Kansas Medical Center, Kansas City, KS
| | - A. P. O’Dea
- University of Kansas Medical Center, Kansas City, KS
| | - P. Sharma
- University of Kansas Medical Center, Kansas City, KS
| | - C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
29
|
Sharma P, Kimler BF, Kennedy T, Smith EJ, Khan QJ, Fabian CJ. Correlation of statin use with breast random periareolar fine needle aspiration (RPFNA) cytomorphology in high risk postmenopausal women. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1031 Background: In vitro studies have demonstrated that statins (HMG CoA reductase inhibitors) suppress tumor growth and proliferation in breast cancer cell lines. Published clinical data on the chemoprotective role of statins in breast cancer are conflicting. Moreover, there are no published studies specifically examining the impact of statin use on breast cancer risk biomarkers in high risk women. We have previously demonstrated that cytologic atypia detected by RPFNA is associated with a 5 fold increase in short term risk of breast cancer in high risk women. The aim of this study was to explore the effect of statin use on breast RPFNA cytomorphology in postmenopausal women at high risk of developing breast cancer (based on personal and family history). Methods: Thehigh risk breast clinic database at the University of Kansas Medical Center was queried from April 2002 to September 2005 for statin use in postmenopausal women. We first identified postmenopausal women who underwent RPFNA while on a statin (cases). Postmenopausal women who underwent RPFNA while not on a statin (controls) were then identified and matched with statin users for known breast cancer risk factors (age, 5 year Gail risk and BMI). Frequencies of categorical variables were assessed using chi-square analysis. Continuous variables were assessed using Mann-Whitney non parametric test. Results: 504 postmenopausal women were identified. Thirty five of these 504 women underwent RPFNA while on statin therapy. For statin users (cases), the median age was 56 years, median 5 year Gail risk was 3.6%, median BMI was 28 and the median duration of statin use was 1.4 years (range 0.3 to 13 yrs). Sixty nine controls were identified. There was no difference between cases and controls with respect to HRT use (54% vs 40%, p=0.22), duration of HRT use (p=0.30) and visual breast density (p=0.80). RPFNA atypia was detected in 11% of cases and 26% of controls (p=0.13). Conclusion: Although prevalence of RPFNA atypia was less frequent among statin users, this difference was not statistically significant in this small cohort of high risk women with relatively short duration of statin use. Larger studies are warranted to investigate this further. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Sharma
- University of Kansas Medical Center, Kansas City, KS
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS
| | - T. Kennedy
- University of Kansas Medical Center, Kansas City, KS
| | - E. J. Smith
- University of Kansas Medical Center, Kansas City, KS
| | - Q. J. Khan
- University of Kansas Medical Center, Kansas City, KS
| | - C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
30
|
Fabian CJ, Kimler BF, Anderson JR, Chamberlain C, Mayo MS, Zalles CM, O’Shaughnessy JA, Lynch HT, Johnson KA, Browne D. Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1001 Background: Arzoxifene (ARZ) is a third generation SERM with efficacy in metastatic breast cancer but lacking uterine agonist activity. Methods: We conducted a randomized, double-blind, placebo-controlled Phase II prevention trial in 199 high risk women assessing the effects of ARZ 20 mg/day on several risk biomarkers. Biomarkers, including cytomorphology of breast epithelial cells obtained by random periareolar FNA (RPFNA) were assessed at baseline and following 6 months of placebo or ARZ. Subjects were stratified by presence or absence of atypia, ER expression, BRCA1/2 mutation, as well as menopause status. Results: At entry, mean age was 47, 52% were premenopausal and 47% of postmenopausal women were taking HRT. Mean 10 year Gail was 6.8% and mean Masood cytology index score was 14.3. The ARZ and placebo groups were well matched. The protocol defined primary endpoint was a decrease in RPFNA cytology Masood index score by ≥3 points at 6 months and required 160 evaluable subjects for 81% power to detect a change from 30% to 52% of subjects showing improvement. For the 181 evaluable subjects, there was no significant difference in the proportion of women achieving ≥3 point improvement (19% placebo vs. 24% ARZ, p=0.46); or in change in mean index score (0.6 placebo vs. 0.9 ARZ, p=0.53). There was also no difference in grade 3 or 4 side effects or dropout prior to 6 months. However, comparing ARZ to placebo, there was favorable modulation of the two risk biomarkers, mammographic breast density (p=0.001) and IGF-1:IGFBP-3 ratio (p=0.001), and reduction in bone turnover biomarker osteocalcin (p= 0.002), but without an increase in endometrial thickness. Conclusions: Although improvement in cytomorphology after 6 months of ARZ was not shown, the acceptable side effect profile and favorable modulation of other biomarkers (breast density, IGF-1:IGFBP-3, osteocalcin) provides support for continued evaluation of ARZ as a breast cancer prevention agent. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - J. R. Anderson
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - C. Chamberlain
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - M. S. Mayo
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - C. M. Zalles
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - J. A. O’Shaughnessy
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - H. T. Lynch
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - K. A. Johnson
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - D. Browne
- University of Kansas Medical Center, Kansas City, KS; Yale University, New Haven, CT; US Oncology, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| |
Collapse
|
31
|
Kimler BF, Ursin G, Fabian CJ, Anderson JR, Chamberlain C, Mayo MS, O’Shaughnessy JA, Lynch HT, Johnson KA, Browne D. Effect of the third generation selective estrogen receptor modulator arzoxifene on mammographic breast density. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.562] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
562 Background: Arzoxifene (ARZ) is currently being studied for treatment of breast cancer patients in a Phase II trial because of tamoxifen-like efficacy but lack of uterine agonist effect. We conducted a Phase II chemoprevention trial in women at high risk for development of breast cancer on the basis of personal or family history. Methods: Potential subjects had multiple biomarkers assessed, including random periareolar fine needle aspiration (RPFNA) with breast epithelial cells processed for cytomorphology and immunocytochemistry. Women who exhibited cytologic hyperplasia ± atypia were eligible for enrollment. Subjects were stratified on the basis of atypia, estrogen receptor expression, menopause status, germline BrCa1/2 mutation status, and accrual site. Subjects were randomized (double-blind) between placebo and ARZ (LY353381.HCI, 20 mg daily) for 6 mo, with an option to continue on study for another 6 mo while receiving open-label ARZ. Assessments conducted at baseline, 6 mo, and 12 mo included mammographic breast density. Mammograms were digitized to image files which were cropped to remove labels and dates, and then identified by a study subject ID number and a random coding for baseline, 6 or 12 mo. This allowed the reader (GU) to view the three files for a subject, but to remain blinded as to the sequence of the films or the study agent. The files were assessed for mammographic density using the Madena computer-assisted system. Results: Of 199 subjects enrolled on the study, 52% were pre-menopausal; with 101 women randomized to placebo and 98 to ARZ. At baseline, mean values were comparable for placebo and ARZ groups for breast area (∼244 cm2), total dense area (∼100 cm2), and the percent of the breast at increased density (41.3% vs 46.2%). After 6 mo, there were minimal changes in total breast area (P=0.13); but statistically significant decreases (P<0.001) for the comparison of placebo vs ARZ (2-sided T-test) for change in both dense area (+3.8 vs −12.9 cm2) and percent breast density (+0.8% vs −4.6%). Conclusions: The 3rd generation SERM arzoxifene administered for 6 mo produces statistically significant decreases in mammographic breast density relative to placebo in women at high risk for development of breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - G. Ursin
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - J. R. Anderson
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - C. Chamberlain
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - M. S. Mayo
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - J. A. O’Shaughnessy
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - H. T. Lynch
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - K. A. Johnson
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| | - D. Browne
- University of Kansas Medical Center, Kansas City, KS; University of Southern California, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Creighton University, Omaha, NE; National Cancer Institute, Bethesda, MD
| |
Collapse
|
32
|
Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 2006; 48:258-67. [PMID: 16430472 DOI: 10.1111/j.1365-2559.2005.02322.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
AIMS Immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) are both commonly used assays for evaluation of HER-2/neu status in breast cancer. However, there is still no consensus on which method is most predictive of patient response to Herceptin. Recently, the automated cellular imaging system (ACIS) has been shown to improve the accuracy and reproducibility in scoring IHC. Our aim was to compare the results of HER-2/neu expression and gene amplification in the same patients by IHC using the ACIS system and by FISH. METHODS AND RESULTS Two hundred and forty-seven breast cancer cases were studied. The concordance rate between IHC-ACIS (> or = 2.2) and FISH (> or = 2.0) was 94%. Fifteen patients were discordant; three had borderline FISH values and three had borderline IHC values. The other nine discordant cases consisted of five IHC-ACIS+, FISH- and six IHC-ACIS-, FISH+. HER-2/neu overexpression was more common in tumours that were high-grade, aneuploid, progesterone receptor and bcl-2 negative, with MIB-1 > 10%. CONCLUSION HER-2/neu assessment by the ACIS is reliable, rapid and inexpensive, and correlates highly with results obtained by FISH.
Collapse
MESH Headings
- Adenocarcinoma/chemistry
- Adenocarcinoma/genetics
- Adenocarcinoma, Mucinous/chemistry
- Adenocarcinoma, Mucinous/genetics
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/analysis
- Breast Neoplasms/chemistry
- Breast Neoplasms/genetics
- Carcinoma, Ductal, Breast/chemistry
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Lobular/chemistry
- Carcinoma, Lobular/genetics
- Carcinoma, Medullary/chemistry
- Carcinoma, Medullary/genetics
- Carcinoma, Squamous Cell/chemistry
- Carcinoma, Squamous Cell/genetics
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Image Processing, Computer-Assisted/methods
- Immunohistochemistry/methods
- In Situ Hybridization, Fluorescence
- Middle Aged
- Receptor, ErbB-2/analysis
- Receptor, ErbB-2/biosynthesis
- Receptor, ErbB-2/genetics
Collapse
Affiliation(s)
- O W Tawfik
- Department of Radiation Oncology, Division of Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Breast tissue and duct fluid provide a rich source of biomarkers to both aid in the assessment of short-term risk of developing breast cancer and predict and assess responses to prevention interventions. There are three methods currently being utilized to sample breast tissue in asymptomatic women for risk assessment: nipple-aspirate fluid (NAF), random periareolar fine-needle aspiration (RPFNA) and ductal lavage. Prospective single-institution trials have shown that the presence of atypical cells in NAF fluid or RPFNA specimens is associated with an increased risk of breast cancer. Furthermore, RPFNA-detected atypia has been observed to further stratify risk based on the commonly used Gail risk-assessment model. A prospective trial evaluating risk prediction on the basis of atypical cells in ductal-lavage fluid is ongoing. The ability of other established non-genetic biomarkers (mammographic breast density; serum levels of bioavailable estradiol, testosterone, insulin-like growth factor-1 and its insulin like growth factor binding protein-3) to stratify risk based on the Gail model is as yet incompletely defined. Modulation of breast intra-epithelial neoplasia (i.e. hyperplasia with or without atypia) with or without associated breast-tissue molecular markers, such as proliferation, is currently being used to evaluate response in Phase II chemoprevention trials. RPFNA has been the method most frequently used for Phase II studies of 6-12 months duration. However, ductal lavage, RPFNA and random and directed core needle biopsies are all being utilized in ongoing multi-institutional Phase II studies. The strengths and weaknesses of each method are reviewed.
Collapse
Affiliation(s)
- C J Fabian
- Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KA 66160, USA.
| | | | | | | |
Collapse
|
34
|
Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS. Breast cancer chemoprevention Phase IB evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. J. Fabian
- University of Kansas Medical Center, Kansas City, KS
| | - B. F. Kimler
- University of Kansas Medical Center, Kansas City, KS
| | - J. Anderson
- University of Kansas Medical Center, Kansas City, KS
| | - O. W. Tawfik
- University of Kansas Medical Center, Kansas City, KS
| | - M. S. Mayo
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
35
|
Ratliff BE, Bean G, Marcom PK, Scott JV, Yee L, Kimler BF, Fabian CJ, Zalles CM, Shaw H, Seewaldt VL. RARbeta P2 promoter methylation: Potential biomarker for use with breast Random Periareolar Fine Needle Aspiration in breast cancer risk assessment. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- B. E. Ratliff
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - G. Bean
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - P. K. Marcom
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - J. V. Scott
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - L. Yee
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - B. F. Kimler
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - C. J. Fabian
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - C. M. Zalles
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - H. Shaw
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| | - V. L. Seewaldt
- Duke University, Durham, NC; Ohio State University, Columbus, OH; University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
36
|
Fabian CJ, Kimler BF. Breast cancer risk prediction: should nipple aspiration fluid cytology be incorporated into clinical practice? J Natl Cancer Inst 2001; 93:1762-3. [PMID: 11734584 DOI: 10.1093/jnci/93.23.1762] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Abstract
Although tamoxifen appears to markedly reduce breast cancer risk in women with a prior diagnosis of atypical hyperplasia or in situ carcinoma, it is not clear what other groups of women receive substantial benefit. Major breast chemoprevention priorities are to (1) develop new agents that (a) have fewer side effects, (b) are effective in ER--as well as tamoxifen-resistant precancerous tissue, and (c) are compatible with hormone therapy; and (2) develop efficient clinical strategies including prognostic and predictive morphologic and molecular biomarkers. Breast tissue may be repeatedly sampled for evidence of intraepithelial neoplasia by fine needle aspiration, ductal lavage, or needle biopsy to select candidates at highest short-term risk as well as to monitor response in small proof of principle studies prior to a large cancer incidence trial. Molecular marker expression may also be used to select a cohort most likely to respond to a particular agent. A large number of new agents are attractive as potential prevention agents and some are already in clinical prevention testing. Compounds which should be effective in ER + precancerous tissue but may have a better side-effect profile include new selective estrogen receptor modulators which lack uterine estrogen agonist activity, isoflavones, aromatase inactivators/inhibitors for postmenopausal women, and gonadotropin-releasing hormone regimens for premenopausal women. Retinoids, rexinoids, and deltanoids may be efficacious in ER+ tissue resistant to tamoxifen. Agents which should theoretically have activity in ER- or ER+ precancerous tissue include polyamine synthesis inhibitors, tyrosine kinase inhibitors, combined demethylating agents and histone deacetylase inhibitors, as well as metalloprotease and angiogenesis inhibitors. Sample Phase I and Phase II clinical trial designs are reviewed using modulation of molecular markers and breast intraepithelial neoplasia as the major endpoints.
Collapse
Affiliation(s)
- C J Fabian
- University of Kansas Medical Center, Kansas City 66160-7320, USA.
| | | |
Collapse
|
38
|
Abstract
The demonstration by the National Surgical Adjuvant Breast Project (NSABP) that 5 years of tamoxifen therapy is associated with an approximate 50% reduction in breast cancer incidence in high-risk women was a milestone in breast cancer prevention. Because tamoxifen is associated with increased risk of side-effects such as hot flashes, menstrual abnormalities, uterine cancer, and thromboembolic phenomena, its use will not be advisable or acceptable for all high-risk women. Women over 50 years of age appear to be at highest risk for serious adverse events, such as uterine cancer and thromboembolic phenomena. Individuals in whom tamoxifen-associated breast cancer risk reduction appears to outweigh risk of serious side-effects include women with prior in situ or estrogen receptor (ER)-positive invasive cancer, atypical hyperplasia, and/or women ages 35-49 with a calculated Gail 5-year risk of > or =1.7%, hysterectomized women aged 50 and older with a 5-year Gail risk of > or =2.5%, and nonhysterectomized women aged 50 and older with a 5-year Gail risk of >5.0%. It is not yet clear whether tamoxifen can reduce breast cancer incidence in women with BRCA1 and BRCA2 mutations, although preliminary evidence favors benefit for at least those with a BRCA2 mutation. Raloxifene is a selective ER modulator with less uterine estrogen agonist activity than tamoxifen, and it is hoped that it will result in fewer uterine cancers but will be equally efficacious in reducing the risk of breast cancer. The NSABP is currently conducting a randomized study of tamoxifen versus raloxifene in high-risk postmenopausal women. Approximately one third of invasive cancers are ER negative. Tamoxifen does not reduce the incidence of ER-negative cancers, nor does it appear to be effective in preventing the appearance of one third of ER-positive cancers. Priorities in prevention research are to develop (a) biomarkers to refine short-term risk assessments based on epidemiologic models, (b) biomarkers predictive of response to specific classes of preventive agents, (c) drugs with fewer side-effects and/or effective in ER-negative or ER-positive tamoxifen-resistant precancerous disease, and (d) efficient clinical trial models to assess new agent efficacy. Breast intraepithelial neoplasia (IEN) may be sampled by minimally invasive techniques and is an attractive short-term risk biomarker. Molecular abnormalities observed in IEN may be used to select potential agents for testing/therapy, and modulation of these abnormalities may be used in phase I trials to select appropriate doses and in phase II trials to assess response. Breast density volume and certain serum markers such as insulin-like growth factor-1 are also being studied as potential risk and response biomarkers. Reversal or prevention of advanced IEN as well as modulation of other risk biomarkers in randomized phase II and phase III trials is being evaluated as a means of more efficiently evaluating prevention drugs in the future. A number of agents are being developed that target molecular abnormalities in IEN, have fewer or different side effects than tamoxifen, and may be effective in ER-negative or tamoxifen-resistant disease.
Collapse
Affiliation(s)
- C J Fabian
- University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
| | | |
Collapse
|
39
|
Abstract
A large number of new potential chemoprevention agents are available that target molecular abnormalities found in estrogen receptor (ER)-negative and/or ER-positive precancerous breast tissue and have side effect profiles that differ from tamoxifen. Classes of agents currently undergoing evaluation in clinical prevention trials or those for which testing is planned in the near future include new selective ER modulators, aromatase inactivators/inhibitors, gonadotrophin-releasing hormone agonists, monoterpenes, isoflavones, retinoids, rexinoids, vitamin D derivatives, and inhibitors of tyrosine kinase, cyclooxygenase-2, and polyamine synthesis. New clinical testing models will use morphological and molecular biomarkers to select candidates at highest short-term risk, to predict the response to a particular class of agent, and to assess the response in phase II prevention trials. If validated, morphological and molecular markers could eventually replace cancer incidence as an indicator of efficacy in future phase III trials.
Collapse
Affiliation(s)
- C J Fabian
- University of Kansas Medical Center, Kansas City, Kansas 66160-7320, USA.
| |
Collapse
|
40
|
Fabian CJ, Kimler BF, Mayo MS. RESPONSE: Re: Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model. J Natl Cancer Inst 2001; 93:68. [PMID: 11136851 DOI: 10.1093/jnci/93.1.68-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- CJ Fabian
- University of Kansas Medical Center, Kansas City
| | | | | |
Collapse
|
41
|
Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, Mayo MS. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000; 92:1217-27. [PMID: 10922407 DOI: 10.1093/jnci/92.15.1217] [Citation(s) in RCA: 225] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND : Biomarkers are needed to refine short-term breast cancer risk estimates from epidemiologic models and to measure response to prevention interventions. The purpose of our study was to determine whether the cytologic appearance of epithelial cells obtained from breast random periareolar fine-needle aspirates or molecular marker expression in these cells was associated with later breast cancer development. METHODS : Four hundred eighty women who were eligible on the basis of a family history of breast cancer, prior precancerous biopsy, and/or prior invasive cancer were enrolled in a single-institution, prospective trial. Their risk of breast cancer according to the Gail model was calculated, and random periareolar fine-needle aspiration was performed at study entry. Cells were characterized morphologically and analyzed for DNA aneuploidy by image analysis and for the expression of epidermal growth factor receptor, estrogen receptor, p53 protein, and HER2/NEU protein by immunocytochemistry. All statistical tests are two-sided. RESULTS : At a median follow-up time of 45 months after initial aspiration, 20 women have developed breast cancer (invasive disease in 13 and ductal carcinoma in situ in seven). With the use of multiple logistic regression and Cox proportional hazards analysis, subsequent cancer was predicted by evidence of hyperplasia with atypia in the initial fine-needle aspirate and a 10-year Gail projected probability of developing breast cancer. Although expression of epidermal growth factor receptor, estrogen receptor, p53, and HER2/NEU was statistically significantly associated with hyperplasia with atypia, it did not predict the development of breast cancer in multivariable analysis. CONCLUSION : Cytomorphology from breast random periareolar fine-needle aspirates can be used with the Gail risk model to identify a cohort of women at very high short-term risk for developing breast cancer. We recommend that cytomorphology be studied for use as a potential surrogate end point in prevention trials.
Collapse
Affiliation(s)
- C J Fabian
- Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City 66160-7820, USA.
| | | | | | | | | | | | | |
Collapse
|
42
|
Kimler BF, Fabian CJ, Wallace DD. Breast cancer chemoprevention trials using the fine-needle aspiration model. J Cell Biochem Suppl 2000; 34:7-12. [PMID: 10762008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Selection of surrogate endpoint biomarkers (SEBs) and appropriate study design are two of the main challenges in evaluating potential chemopreventive agents. In a prospective random fine-needle aspiration (FNA) study of women at high risk of development of breast cancer, we previously demonstrated that cytologic evidence of epithelial hyperplasia with or without atypia, as well as abnormalities of several cellular biomarkers (DNA ploidy; immunocytochemical expression of p53, EGFR, ER, and/or Her-2/neu), were more prevalent in high-risk women than in low-risk controls. We also demonstrated that the subsequent development of breast cancer was best predicted by an initial presentation of hyperplasia with atypia, as well as by multiple biomarker abnormalities. These findings indicate that FNA cytology and biomarkers can be used to identify women who are appropriate subjects for chemoprevention trials, and can then be used as surrogate endpoint biomarkers to monitor efficacy of potential agents. An example of this use in an ongoing single-agent phase II trial is provided. Several options for study design of possible multi-agent breast cancer chemoprevention trials are discussed, depending upon the existing preclinical and clinical data, the questions being asked, and the number of eligible subjects available.
Collapse
Affiliation(s)
- B F Kimler
- Department of Radiation Oncology, University of Kansas Medical Center, Kansas City 66160-7321, USA.
| | | | | |
Collapse
|
43
|
Klemp J, Brady D, Frank TS, Kimler BF, Fabian CJ. Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a phase II chemoprevention trial. Eur J Cancer 2000; 36:1209-14. [PMID: 10882858 DOI: 10.1016/s0959-8049(00)00112-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
It is unknown what proportion of women at high risk for breast cancer, entering phase II chemoprevention trials, have BRCA1/2 alterations, and whether their initial biomarker patterns or response to preventive interventions will differ between carriers and non-carriers. As part of a 6-month phase II chemoprevention trial of diflouromethlyornithine (DFMO), high-risk subjects (family history, prior precancerous breast disease or prior breast cancer), who had random peri-areolar fine needle evidence of epithelial hyperplasia with or without atypia, were offered genetic counselling and testing at the completion of their study participation. 97% of the 119 women eligible for testing underwent BRCA1/2 gene sequencing, 3 declined. 26 (22%) of the 116 women had an alteration in BRCA1/2. Known deleterious mutations were present in 3 (3%), uncertain significance mutations in 19 (16%), and probable polymorphisms in 6 (5%). There does not appear to be a difference in initial biomarker distribution between participants with and without germ line alterations.
Collapse
Affiliation(s)
- J Klemp
- Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160-7418, USA
| | | | | | | | | |
Collapse
|
44
|
Abstract
Several models are being explored for use in the phase I and phase II evaluation of breast cancer chemoprevention agents. The short-term DCIS/small invasive cancer model is probably best used in late phase I trials in conjunction with agents likely to have activity in the progression phase of neoplastic development in addition to activity in earlier phases. The core biopsy or FNA hyperplasia models may be best used with drugs that are likely to have activity primarily in the promotion phase of neoplastic development and that are suitable for longer duration trials lasting several months to years. Morphology currently is the key surrogate endpoint biomarker for assessing efficacy in phase II trials. Other biomarkers that may undergo modulation will have to be validated, in that modulation will have to be shown to be directly related to decreased cancer risk in subsequent phase III trials. Only then can they be considered as validated surrogate endpoint biomarkers and used as stand-alone efficacy markers in phase II trials. Despite accrual challenges and technologic hurdles, interest in phase I and phase II chemoprevention trials is high.
Collapse
Affiliation(s)
- C J Fabian
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, USA
| | | | | | | | | | | |
Collapse
|
45
|
Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J Cell Biochem Suppl 1998; 28-29:101-10. [PMID: 9589354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
In a prospective pilot study, we performed breast fine needle aspirations (FNAs) on 224 high-risk and 30 low-risk women and analyzed these aspirates for cytologic changes and biomarker abnormalities of aneuploidy and overexpressed estrogen receptor (ER), epidermal growth factor receptor (EGFR), p53 and HER-2/neu. High-risk women had a first-degree relative with breast cancer (74%), prior biopsy indicating premalignant breast disease (25%), a history of breast cancer (13%), or some multiple of these risk factors (12%). Median ages of the high- and low-risk groups were 44 and 42, respectively. Seventy percent of high-risk and 17% of low-risk women had cytologic evidence of hyperplasia with or without atypia (P < .0001). Aneuploidy and overexpression of EGFR and p53 occurred in 27, 37, and 29% of high-risk subjects but only 0, 3, and 3% of low-risk subjects (P < .0023). Overexpression of ER and HER-2/neu occurred in 7 and 20% of high-risk women but in none of the low-risk subjects. Biomarker abnormalities were more frequent with increasing cytologic abnormality. Restricting the analysis to those 3 biomarkers most frequently overexpressed in the high-risk group (ploidy, EGFR, p53), 13% of high-risk women with normal cytology, 19% of high-risk women with epithelial hyperplasia, and 49% of high-risk women with hyperplasia with atypia had abnormalities of 2 or more of these 3 biomarkers (P = .00004). At a median follow-up of 32 months, four women have been diagnosed with invasive cancer and two with ductal carcinoma in situ (DCIS). Later detection of these neoplastic conditions was associated (P < or = .016) by univariate analysis with prior FNA evidence of hyperplasia with atypia; overexpression of p53 and EGFR; the modified Gail risk of breast cancer development at 10 years; and multiple biomarker abnormalities. By multivariate analysis, later detection of cancer was primarily predicted by the number of biomarker abnormalities in the 3-test battery (P = .0005) and secondarily by the Gail risk at 10 years (P = .0049). In turn, hyperplasia with atypia was associated with multiple biomarker abnormalities, particularly p53 and EGFR overexpression. Thus, hyperplasia with atypia and cytologic markers in breast FNAs have promise as risk predictors and as surrogate endpoint biomarkers for breast cancer chemoprevention trials.
Collapse
Affiliation(s)
- C J Fabian
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City 66160-7820, USA
| | | | | | | | | | | |
Collapse
|
46
|
Fabian CJ, Kamel S, Zalles C, Kimler BF. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem Suppl 1996; 25:112-22. [PMID: 9027607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In a prospective pilot study, we performed breast fine needle aspirations (FNAs) on 213 high-risk and 30 low-risk women and analyzed these aspirates for cytologic changes and biomarker abnormalities of aneuploidy and overexpressed estrogen receptor (ER), epidermal growth factor receptor (EGFR), p53 and HER-2/neu. High-risk women were those with a first degree relative with breast cancer (73%), prior biopsy indicating premalignant breast disease (26%), a history of breast cancer (13%), or some multiple of these risk factors (11%). Median ages of the high-risk and low-risk groups were 44 and 42, respectively. Sixty-three percent of the high-risk and 73% of the low-risk group were premenopausal. Sixty-eight percent of the high-risk and 17% of low-risk women had cytologic evidence of hyperplasia with or without atypia (P < .0001). Aneuploidy and overexpression of EGFR and p53 occurred in 25%, 36%, and 28% of high-risk subjects but in less than 4% of low-risk subjects (P < .0002). Overexpression of ER and HER-2/neu occurred in 8% and 19%, respectively of high-risk women; nc low-risk women had these abnormalities. Sixty-eight percent of high-risk women and 7% of low-risk women had abnormalities of one or more of these biomarkers exclusive of cytology. Thirty-one percent of high-risk women, but no low-risk women had abnormalities of two or more biomarkers (P = .0004). Biomarker abnormalities were more frequent with increasing cytologic abnormality. Eighteen percent of women with normal cytology, 29% of women with epithelial hyperplasia and 60% of women with hyperplasia with atypia had abnormalities of two or more biomarkers (P = .048 and < .0001, respectively). Restricting the analysis to those three biomarkers most frequently overexpressed in the high-risk group (ploidy, EGFR, p53), 13% of high-risk women with normal cytology, 20% of high-risk women with epithelial hyperplasia and 51% of high-risk women with atypical hyperplasia had abnormalities of 2 or more of these 3 biomarkers. At a median follow up of two years, 8 of 213 women have been diagnosed with in situ (n = 5) or invasive (n = 3) cancer. Later detection of neoplasia was associated with prior FNA evidence of atypical hyperplasia (P < .0001) and multiple biomarker abnormalities in the 5 test battery (P = .006) by univariate analysis. By multivariate analysis, development and/or detection of cancer was primarily predicted by atypical hyperplasia (P = .0047) and secondarily by multiple biomarker abnormalities (P = 0.021). Atypical hyperplasia, EGFR, and p53 in breast FNAs have promise as risk markers and as surrogate endpoint biomarkers for breast cancer chemoprevention trials.
Collapse
Affiliation(s)
- C J Fabian
- Division of Clinical Oncology, University of Kansas Medical Center, Kansas City 66160-7820, USA
| | | | | | | |
Collapse
|
47
|
Fabian CJ, Kimler BF, McKittrick R, Park CH, Lin F, Krishnan L, Jewell WR, Osborne CK, Martino S, Hutchins LF. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res 1994; 54:5357-62. [PMID: 7923165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
One theoretical method of increasing chemotherapeutic efficacy in breast cancer is to temporarily increase the number of tumor cells in cycle through hormonal recruitment prior to initiation of chemotherapy. In an effort to determine when and if this could be reliably accomplished, 50 women with locally advanced and/or metastatic breast cancer with known estrogen receptor (ER) status were entered into a serial breast biopsy study designed to measure increases in S-phase fraction (SPF) and proliferative index (PI; S + G2 + M) following administration of a high physiological dose of estrogen via estradiol vaginal suppositories prior to chemotherapy. Blood levels of estradiol were maintained in a range (0.5-5 nM) known to increase SPF in vitro. Compliance with suppository administration was monitored by serial blood sampling. Tumors were sampled at 0, 24, 48, 72, and/or 96 h. Thirty-one ER-positive and 9 ER-negative women had evaluable baseline biopsies and at least 1 subsequent biopsy. An increase was seen for SPF in 20 (69%) and for PI in 23 (79%) of 29 ER-positive patients at 48 h after estrogen initiation (95% confidence intervals, 49-85% for SPF and 60-92% for PI); similar increases were seen at 72 h. Median baseline SPF and PI values in ER-positive patients for whom increases were noted at 48 h were 6.2 and 8.5%, respectively. The median relative increases in these patients were 170 and 100%, respectively, at 48 h. The increases observed at 24 h in 4 (SPF) and 6 (PI) of the 9 ER-negative patients could have occurred by chance alone. Twenty-five of the 28 locally advanced (T4 and/or N2-3) patients achieved a complete response during combined modality treatment (estradiol-chemotherapy, mastectomy, and radiation). At a minimum follow-up time of 42 months, estimated 5-year progression-free and overall survivals are 30 and 49%, respectively, with a median time to progression of 35 months. Twenty-two women had metastatic disease (19 also had locally advanced disease). Thirteen had a complete or partial response, with a median duration of 12 months. Median progression-free and over-all survival times for all metastatic patients are 4 and 17 months, respectively. Estimated 5-year survival for metastatic disease patients is 27%. A high physiological dose of estrogen administered to patients with locally advanced ER-positive tumors can reliably increase the tumor SPF and PI within 48 h.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- C J Fabian
- Department of Medicine, University of Kansas Medical Center, Kansas City 66160
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA, Fisher RI. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120:903-12. [PMID: 8172436 DOI: 10.7326/0003-4819-120-11-199406010-00002] [Citation(s) in RCA: 143] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
OBJECTIVE To determine if low-dose involved field radiation after complete remission induction with chemotherapy is effective in preventing relapse and improving survival in patients with stage III or IV Hodgkin disease. DESIGN A randomized controlled trial with a median follow-up time of 8.1 years. SETTING A Southwest Oncology Group multi-institutional study. Patients were entered from university- and community-based practices. PATIENTS 278 adults with clinical or pathologic stage III or IV Hodgkin disease, who achieved complete responses after 6 cycles of MOP-BAP (nitrogen mustard, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine) and who agreed to be randomly assigned to either radiation or no further treatment. INTERVENTION Patients were assigned to either no further treatment or low-dose radiation to all initially involved sites (radiation dose, 2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites). MEASUREMENTS Differences in remission duration, relapse-free survival, and survival. RESULTS Remission duration, relapse-free survival, and overall survival were similar for the two groups (P = 0.09, P > 0.2, and P = 0.14, respectively). Factors that predicted shorter remission duration in a multivariate analysis were nodular sclerosis histology, bulky disease, and receipt of less than 85% of planned chemotherapy. Low-dose radiation improved remission duration in the subgroups of patients with nodular sclerosis and bulky disease. For the 169 patients with nodular sclerosis, the 5-year remission-duration estimate was 82% for the low-dose radiation group and 60% for the no further treatment group (P = 0.002). For all patients with bulky disease, the 5-year remission-duration estimate was 75% for the low-dose radiation group and 57% for the no further treatment group (P = 0.05). No difference in overall survival was noted between low-dose radiation and no further treatment in all patients or major subgroups. The 5-year survival was 86% for all patients who had a complete response as well as for patients in the nodular sclerosis subgroup. CONCLUSIONS Low-dose involved field radiation after MOP-BAP chemotherapy in patients with stage III or IV Hodgkin disease did not prolong remission duration or overall survival in randomized patients. However, remission duration was prolonged in several subgroups of patients, most prominently in those with nodular sclerosis histology.
Collapse
Affiliation(s)
- C J Fabian
- University of Kansas Medical Center, Kansas City
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Fabian CJ, Zalles C, Kamel S, Kimler BF, McKittrick R, Tranin AS, Zeiger S, Moore WP, Hassanein RS, Simon C. Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer. Breast Cancer Res Treat 1994; 30:263-74. [PMID: 7981444 DOI: 10.1007/bf00665967] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Breast tissue biomarkers which accurately predict breast cancer development within a 10 year period in high risk women are needed but currently not available. We initiated this study to determine 1) the prevalence of one or more breast tissue abnormalities in a group of women at high risk for breast cancer, and 2) if the prevalence of biomarker abnormalities is greater in high risk than in low risk women. Eligible high risk women were those with a first degree relative with breast cancer, prior breast cancer, or precancerous mastopathy. Low risk women were those without these or other major identifiable risk factors. Ductal cells were obtained via random fine needle aspirations and cytologically classified. Biomarkers included DNA ploidy, estrogen receptor (ER), and epidermal growth factor receptor (EGFR). The prevalence of DNA aneuploidy was 30%, overexpression of ER 10%, and overexpression of EGFR 35%, in the 206 high risk women whose median 10 year Gail risk (projected probability) of developing breast cancer was 4.5%. The prevalence of aneuploidy and overexpressed EGFR was significantly higher in the high risk women than in the 25 low risk controls (p < 0.002), whose median 10 year Gail risk was 0.7%. The difference in the prevalence of ER overexpression between high and low risk groups was not statistically significant (p = 0.095). This may be due to the low prevalence of overexpressed ER and the small number of controls. A significant difference was noted in the prevalence of one or more abnormal biomarkers between the high risk and low risk women (p < 0.001). A large prospective trial is needed to determine if one or more of these biomarkers, is predictive of breast cancer development.
Collapse
Affiliation(s)
- C J Fabian
- University of Kansas Cancer Center, University of Kansas Medical Center, Kansas City 66160-7820
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Fabian CJ, Zalles C, Kamel S, McKittrick R, Moore WP, Zeiger S, Simon C, Kimler B, Cramer A, Garcia F. Biomarker and cytologic abnormalities in women at high and low risk for breast cancer. J Cell Biochem Suppl 1993; 17G:153-60. [PMID: 7911861 DOI: 10.1002/jcb.240531129] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Fine needle aspirates (FNA) from 106 high-risk women and 25 low-risk women were evaluated for overexpression of estrogen receptor (ER), epidermal growth factor receptor (EGFR), mutant p53, and HER-2/neu by immunocytochemistry, and for aneuploidy by image analysis. Aspirates were also classified cytologically as normal, apocrine metaplasia, epithelial hyperplasia (EH), or dysplasia. High-risk women were those with a first-degree relative with breast cancer (76%), precancerous breast disease (26%), prior cancer of the contralateral breast (9%), or multiple abnormalities (11%). Low-risk women had none of the above risk factors, nor a prior breast biopsy or clinical evidence of fibrocystic disease. The median 10-year Gail risk for the high-risk group was 4%, compared to 0.7% for the low-risk group. There were significant differences (p < 0.01) between high- and low-risk women in the prevalences of hyperplasia (55% versus 12%), dysplasia (19% versus 0%), aneuploidy (32% versus 0%), overexpressed EGFR (32% versus 4%), and overexpressed p53 (29% versus 4%). The prevalence of multiple biomarker abnormalities was also greater in high-risk than in low-risk women (28% versus 0%; p < 0.01). Four percent (4%) of FNAs from high-risk women with normal cytology, 29% of aspirates with hyperplastic cytology, and 60% of those with dysplasia were associated with two or more biomarker abnormalities. The differences in the prevalence of multiple biomarker abnormalities among various cytologic categories were statistically significant (p = 0.02, normal versus EH; p = 0.02, EH versus dysplasia; p < 0.01, normal versus dysplasia).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- C J Fabian
- University of Kansas Cancer Center, Kansas City 66160
| | | | | | | | | | | | | | | | | | | |
Collapse
|